Original Article
Brief Report
Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis
N Engl J Med 2008; 358:2231-2239May 22, 2008
- Abstract
Early-onset, severe retinal dystrophy caused by mutations in the gene encoding retinal pigment epithelium–specific 65-kD protein (RPE65) is associated with poor vision at birth and complete loss of vision in early adulthood. We administered to three young adult patients subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 complementary DNA (cDNA) under the control of a human RPE65 promoter. There were no serious adverse events. There was no clinically significant change in visual acuity or in peripheral visual fields on Goldmann perimetry in any of the three patients. We detected no change in retinal responses on electroretinography. One patient had significant improvement in visual function on microperimetry and on dark-adapted perimetry. This patient also showed improvement in a subjective test of visual mobility. These findings provide support for further clinical studies of this experimental approach in other patients with mutant RPE65. (ClinicalTrials.gov number, NCT00643747.)
Media in This Article
Video
Vitrectomy, Subretinal Injection, and Obstacle Course Before and After Injection.
Figure 1
Images of the Fundus and Maculae before and after Experimental Treatment.Article Activity
- Article
Video
Vitrectomy, Subretinal Injection, and Obstacle Course Before and After Injection.
Leber's congenital amaurosis is a term used to describe a group of recessively inherited, severe, infantile-onset rod–cone dystrophies.1 Mutation of one of several genes, including RPE65, causes disease that involves impaired vision from birth2,3 and typically progresses to blindness in the third decade of life. There is no effective treatment. RPE65 is expressed in the retinal pigment epithelium and encodes a 65-kD protein that is a key component of the visual cycle,1,4-8 a biochemical pathway that regenerates the visual pigment after exposure to light.9-14 A lack of functional RPE65 results in deficiency of 11-cis retinal so that rod photoreceptor cells are unable to respond to light. Cone photoreceptor cells may have access to 11-cis–retinaldehyde chromophore through an alternative pathway that does not depend on retinal pigment epithelium–derived RPE65,15,16 thus allowing cone-mediated vision in children with Leber's congenital amaurosis. However, progressive degeneration of cone photoreceptor cells ultimately results in the loss of cone-mediated vision.
Although the retinal dystrophy caused by defects in RPE65 is severe, features of the disorder suggest that it may respond to gene-replacement therapy. There is useful visual function in childhood, and retinal imaging suggests that photoreceptor-cell death occurs late in the disease process.3 Gene transfer therefore has the potential to improve visual function as well as preserve existing vision. Gene-replacement therapy has been shown to improve visual function in the Swedish Briard dog, a naturally occurring animal model with mutated RPE65.17 Subretinal delivery of recombinant adeno-associated virus vector containing the RPE65 cDNA results in improved retinal function and improved vision, as determined by visual mobility in low light.18-22
The purpose of this study was to determine whether gene therapy for retinal dystrophy caused by RPE65 mutations was associated with immediately obvious adverse events and whether efficacy could be demonstrated in humans. In this exploratory, open-label, single-center study involving three young adults, each of whom received a single subretinal injection of recombinant adeno-associated virus 2/2.hRPE65p.hRPE65, the primary outcome was safety, and the secondary outcome was evidence of efficacy in terms of visual function.
Methods
Patients and Study Design
In this study, we included young adults (17 to 23 years of age) with early-onset, severe retinal dystrophy caused by missense mutations in RPE65 (Table 1 of the Supplementary Appendix, available with the full text of this article at www.nejm.org). We excluded persons with visual acuity in the study eye that was better than 20/120 on the Snellen visual acuity scale, null mutations, and contraindications to systemic immunosuppression, as well as women who were pregnant or lactating. A National Health Service diagnostic laboratory (Manchester Regional Genetics Laboratory) confirmed the genotypes of potential subjects. In each patient, the eye with the worse acuity was selected as the study eye. The contralateral eye was used as a control.
The study was approved by the U.K. Gene Therapy Advisory Committee, the Medicines and Health Products Regulatory Authority, the Moorfields Research Governance Committee, and the local research ethics committee. All patients gave written informed consent. The study was conducted in compliance with Good Clinical Practice guidelines according to the European Clinical Trials Directive (Directive 2001 EU/20/EC) and the Declaration of Helsinki.
Before administration of the vector, we evaluated the retinal structure and function by means of clinical assessment, retinal imaging, psychophysical techniques, and electrodiagnostic methods. Retinal imaging techniques included color fundus photography, fundus autofluorescence imaging, and optical coherence tomography to determine retinal thickness and integrity. We measured visual acuity, contrast sensitivity, color vision, and cone flicker sensitivities. We investigated the patients' visual fields by means of microperimetry (see the Supplementary Appendix), Goldmann dynamic perimetry, and photopic and scotopic (dark-adapted) automated static perimetry (see the Supplementary Appendix). All testing was performed according to standardized, detailed protocols, with controlled room lighting, a dark-adaptation period, and a fixed sequence of test patterns. Both microperimetry and dark-adapted perimetry are fully automated, so there was little opportunity for experimenter bias. We determined the visual mobility of the patients at different illumination levels by measuring their ability to navigate a simulated street scene (Figure 1 in the Supplementary Appendix). Electrophysiological evaluation included full-field, pattern, and multifocal electroretinography performed to incorporate the standards and guidelines of the International Society for Clinical Electrophysiology of Vision.
We repeated assessments of visual function and immune status (see below) at 2, 4, 6, and 12 months (the latter for Patient 1 only; Patients 2 and 3 have not yet reached the 12-month point) after administration of the vector. The end point for toxic effects for each patient was a grade 3 adverse event, defined as loss of visual acuity by 15 or more letters according to the Early Treatment Diabetic Retinopathy Study scale (on which 20/20 denotes perfect vision), or severe, unresponsive intraocular inflammation. The end point for efficacy for each patient was defined as any improvement in visual function that was greater than the test–retest difference for each technique. The assay of immune response and detection of disseminated recombinant adeno-associated virus are described in the Supplementary Appendix.
Recombinant Adeno-Associated Virus and Subretinal Delivery
The tgAAG76 vector is a recombinant adeno-associated virus vector of serotype 2. The vector contains the human RPE65 coding sequence driven by a 1400-bp fragment of the human RPE65 promoter and terminated by the bovine growth hormone polyadenylation site, as described elsewhere.21 The vector was produced by Targeted Genetics Corporation according to Good Manufacturing Practice guidelines with the use of a B50 packaging cell line,23 an adenovirus–adeno-associated virus hybrid shuttle vector containing the tgAAG76 vector genome, and an adenovirus 5 helper virus. The vector was filled in a buffered saline solution at a titer of 1×1011 vector particles per milliliter and frozen in 1-ml aliquots at −70°C.
Patients 1, 2, and 3 underwent surgery on February 7, April 25, and July 11, 2007, respectively. After three-port vitrectomy, we administered up to 1 ml of recombinant adeno-associated virus vector by means of a subretinal cannula (de Juan, Synergetics) to the subretinal space of one eye, involving up to one third of the total retinal area, including the macula. To reduce the possibility of clinically significant intraocular inflammation, patients were given a 5-week course of oral prednisolone, at a daily dose of 0.5 mg per kilogram of body weight for 1 week before administration of the vector, 1 mg per kilogram for the first week after administration, 0.5 mg per kilogram for the second week, 0.25 mg per kilogram for the third week, and 0.125 mg per kilogram for the fourth week. Patients received betamethasone and cefuroxime subconjunctivally at the completion of surgery and topical treatment with 0.5% chloramphenicol four times a day for 7 days, 0.1% dexamethasone four times a day for 4 weeks, and 1% atropine twice a day for 7 days after surgery. We performed a clinical examination, fundus photography, and ocular coherence tomography (Stratus OCT, Carl Zeiss Meditec) at frequent intervals in the early postoperative period to monitor for retinal reattachment and to identify any intraocular inflammation.
Results
Each patient had little or no vision in low light from an early age but retained some limited visual function in good lighting conditions. We selected these patients because they retained a limited degree of residual retinal function despite advanced retinal degeneration, and they might therefore be expected to benefit from intervention.
We performed vitrectomy and subretinal injection of the vector without complication in each patient (Figure 1Figure 1
Images of the Fundus and Maculae before and after Experimental Treatment. and video). The vitreous gel was relatively degenerate; a posterior vitreous detachment was present in Patient 2 and was readily induced in Patients 1 and 3 by active aspiration at the optic disk with the use of the vitreous cutter. To deliver the vector to the relatively well-preserved retina at the posterior pole, we performed a retinotomy superior to the proximal part of the superotemporal vascular arcade. To minimize injection of the vector into the vitreous or choroid, we first induced a small detachment of the neurosensory retina, using Hartmann's solution, before injecting up to 1 ml of recombinant adeno-associated virus vector (thus creating a “bleb”) through the same single retinotomy. In Patient 2, the bleb of the vector extended spontaneously across the macula. We actively manipulated the bleb in Patients 1 and 3 — to involve the macula — by injecting air into the vitreous cavity. We caused no iatrogenic retinal tears, and we left the vector in situ under fluid without retinopexy or intraocular tamponade. On clinical examination 24 hours after surgery, the induced retinal detachment had almost fully resolved in each patient (Figure 1A). Optical coherence tomography showed minimal persistent subretinal fluid at the macula that resolved 2 to 3 days after surgery (Figure 1B). On clinical examination, the appearance of the retinas was unchanged for the duration of the follow-up period (up to 12 months).We detected no dissemination of the vector, as assessed by means of polymerase-chain-reaction amplification of DNA isolated from samples of tears, serum, and saliva collected 1 day and 30 days after administration of the vector and from semen collected at 30 days (data not shown). We observed mild, self-limiting postoperative intraocular inflammation, which typically follows vitrectomy. There were no other adverse events. We found no evidence of cystoid macular edema clinically or on optical coherence tomography. We detected no specific cellular or humoral immune responses to adeno-associated virus capsid (Figure 2 of the Supplementary Appendix) or specific humoral responses to the transgene product (Figure 2 and Table 2 of the Supplementary Appendix). We detected a small increase in nonspecific activation of T cells in two patients, which is consistent with a rebound in the numbers of some lymphocyte subgroups after the withdrawal of corticosteroids (Figure 2A of the Supplementary Appendix).
Visual acuity decreased predictably in association with the temporary retinal detachment induced by administration of the vector and returned to preoperative levels by 6 months (Table 1Table 1
Visual Acuities and Contrast Sensitivities at Baseline and in the Postoperative Period.). We observed no clinically significant improvement in visual acuity in any of the three patients (Table 1) or any change in peripheral visual fields on Goldmann perimetry testing. We detected no change in retinal responses to flash or pattern electroretinography. Before surgery, Patient 2 had high-amplitude nystagmus, which did not change after treatment.Microperimetry showed no change in retinal function in Patients 1 and 2 but improved retinal function in Patient 3 (Figure 2AFigure 2
Assessment of Visual Function by Microperimetry and Dark-Adapted Perimetry.). The baseline data for Patient 3 were obtained from the average of two measurements taken 1 week apart. Measurements were performed on the same retinal loci by registering the fundus image with the baseline image. In an area extending from the outer macula to a point beyond the major vascular arcade, the retinal sensitivity improved progressively in the right (study) eye by as much as 14 dB (a factor of 25). Thus, the patient could see small spots of light that were 1/25 as bright as those that could be seen before treatment. There was no improvement in the left (control) eye.Dark-adapted perimetry showed no change in retinal function in Patients 1 and 2 but showed improved retinal function in Patient 3 (Figure 2). In Patients 1 and 2, there was no single location that showed significant improvement or deterioration (P<0.05). In Patient 3, some locations in the left (control) eye had yellow bars representing nonsignificant decreases and red bars representing significant decreases in sensitivity. In the right (study) eye, 37 locations showed significant improvements in sensitivity (P<0.01). The mean sensitivity at nine locations in the inferonasal region improved from 4 dB at baseline to 26 dB after treatment, and nine locations in the inferotemporal quadrant improved from 7 dB to 28 dB. This finding is equivalent to an improvement in sensitivity of more than 20 dB for these 18 locations, or 100 times the sensitivity threshold observed at baseline.
Visual mobility in low light was unchanged in Patients 1 and 2 but improved in Patient 3 (Figure 3Figure 3
Assessment of Visual Mobility. and video). In bright conditions, the visually guided mobility in Patient 3 was within normal limits at baseline and follow-up. Under low illumination at baseline, the visual performance of Patient 3 was very poor with the study eye as compared with the control eye (with which he made no errors). At follow-up, we observed a small change for the control eye. We attribute this change to a general learning effect; a similar improvement in travel time to complete the course under dim illumination was also observed in Patient 1. However, after administration of the vector, the travel time for Patient 3 improved from 77 seconds to 14 seconds for the study eye, and mobility errors decreased from 8 to 0. Similar results were obtained in a second follow-up test 4 weeks later.Discussion
Recombinant adeno-associated virus 2/2 vector efficiently transduces retinal pigment epithelial cells after subretinal delivery in animal models.24 We investigated the feasibility of subretinal vector injection in patients with advanced retinal degeneration and found that we could achieve this outcome predictably and without immediate adverse events, using a transvitreal, transretinal approach after pars plana vitrectomy. A relatively degenerate vitreous facilitated detachment and removal of the posterior vitreous cortex, which otherwise might have resisted passage of the fine cannula. We found that we could deliver through a single retinotomy up to 1 ml of vector subretinally without causing tears in thinned, degenerate retina. To investigate the effect of RPE65 gene therapy on macular function, we included the macula in the area of vector administration by injection of air into the vitreous cavity when necessary. An important concern was that detachment of the neurosensory retina as a result of subretinal injection could adversely affect vision in the long term, particularly if the detachment involved the macula. We found that the induced retinal detachment resolved spontaneously and fully within a few days after injection, with subsequent recovery of vision to preexisting levels. We did not identify any clinically significant adverse effect of subretinal vector delivery, and the absence of systemic dissemination suggests that any extraocular leakage of vector from the subretinal space was minimal.
To minimize the possibility of intraocular inflammation elicited by vector capsid proteins, we used perioperative systemic immunosuppressive agents. Because of concerns about the possibility of immune responses to the transgene product, we used a tissue-specific promoter and excluded patients with null mutations. We observed no clinically significant intraocular inflammation and detected no immune responses to either adeno-associated virus capsid or RPE65.
We found consistent evidence, on the basis of both microperimetry and dark-adapted perimetry, of improved vision in one patient (Patient 3). The improvement in his visual mobility in low light was also substantially greater than that which would be due to a modest learning effect and was consistent with the improvement in visual function established by means of perimetry. It is not clear whether the improvement in visual responses in the peripheral macula is rod-mediated or cone-mediated. Neither can we be sure that the improvement in visual function is entirely due to enhanced levels of RPE65 in the retina. Evidence for this could be obtained only by biopsy of retinal material, which would be unsafe and unethical. Central macula function and visual acuity did not improve, despite exposure of this region to the vector; this may be due either to amblyopia (i.e., the study eye was amblyopic) or to a requirement for higher levels of RPE65 at the fovea. Visual function improved in only one patient (Patient 3); he had better baseline visual acuity in both the study (amblyopic) eye and the control eye than either of the other patients. He was not the youngest patient, but he probably had less advanced retinal disease at baseline, which may explain why the improvement in this patient was not observed in the other patients. Whether further retinal degeneration is delayed in any of the patients will become apparent only after several years.
The results of this study suggest that subretinal administration of recombinant adeno-associated virus vector is not associated with immediate adverse events in patients with severe retinal dystrophy and that adeno-associated virus–mediated RPE65 gene therapy can lead to modest improvements in visual function, even in patients with advanced degeneration. Our findings provide support for the development of further clinical studies in children with RPE65 deficiency; these children are more likely to benefit than adults.
Supported by grants from the U.K. Department of Health, the British Retinitis Pigmentosa Society, and the Special Trustees of Moorfields Eye Hospital, and by the Sir Jules Thorn Charitable Trust, the Wellcome Trust, the European Union (EVI-Genoret and Clinigene programs), the Medical Research Council, Foundation Fighting Blindness, Fight for Sight, the Ulverscroft Foundation, Fighting Blindness (Ireland), Moorfields Eye Hospital, and Institute of Ophthalmology Biomedical Research Centre for Ophthalmology, University College London.
Drs. Bainbridge and Ali report being the inventors associated with a U.S. patent application assigned to University College London and Targeted Genomics Corporation entitled, “Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea”; Drs. Fitzke and Viswanathan report being two of the inventors of Progressor software, the intellectual property rights for which are owned by University College London and Moorfields Eye Hospital and licensed to Medisoft; Dr. Carter reports being an employee of Targeted Genetics and receiving consulting fees from Sangamo Biosciences.
No other potential conflict of interest relevant to this article was reported.
Drs. Bainbridge and Smith contributed equally to this article.
This article (10.1056/NEJMoa0802268) was published at www.nejm.org on April 27, 2008.
We thank Andrew Dick and the U.K. RPE65 Gene Therapy Data and Safety Monitoring Committee; Alan Bird and the Moorfields Eye Hospital RPE65 Gene Therapy Advisory Committee; Vivien Perry and Moorfields Pharmaceuticals; Graeme Black, for help with genotyping; David Wong, for advice on surgical techniques; and the patients and their families for their effort and commitment.
Source Information
From the Institute of Ophthalmology, University College London (J.W.B.B., A.J.S., S.S. Barker, S.R., R.H., K.B., A.V., G.E.H., A.S., S.S. Bhattacharya, F.W.F., G.S.R., A.T.M., R.R.A.); Moorfields Eye Hospital (J.W.B.B., A.V., G.E.H., A.T.M.); the National Institute of Health Research Biomedical Research Centre for Ophthalmology, University College London and Moorfields Eye Hospital (J.W.B.B., G.S.R., A.T.M., R.R.A.); the Department of Civil and Environmental Engineering, University College London (N.T.); and the Institute of Child Health, University College London (A.J.T., R.R.A.) — all in London; Michigan State University, East Lansing (S.P.-J.); and Targeted Genetics Corporation, Seattle (B.J.C.).
Address reprint requests to Dr. Ali at the Institute of Ophthalmology, University College London, Bath St., London EC1V 9EL, United Kingdom, or at r.ali@ucl.ac.uk.
Appendix
The following investigators, who are members of the Moorfields Eye Hospital and University College London Eye Gene Therapy Study Group, participated in this trial: G.W. Aylward, D. Boampong, C. Broderick, P. Buch, C. Childs, Y. Duran, D. Ehlich, S. Falk, M. Feely, T. Fujiyama, F. Ikeji, V. Luong, A. Milliken, R. Maclaren, P. Moradi, F. Mowat, M. Richardson, C. Ripamonti, A.G. Robson, H. Rostron, I. Russell-Eggitt, P. Schlottmann, M. Tschernutter, and N. Wasseem.
- References
References
1
Hanein S ,Perrault I ,Gerber S , et al. Leber congenital amaurosis: comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, and genotype-phenotype correlations as a strategy for molecular diagnosis. Hum Mutat 2004;23:306-317
CrossRef | Web of Science | Medline2
Lorenz B ,Gyurus P ,Preising M , et al. Early-onset severe rod-cone dystrophy in young children with RPE65 mutations. Invest Ophthalmol Vis Sci 2000;41:2735-2742
Web of Science | Medline3
Paunescu K ,Wabbels B ,Preising MN ,Lorenz B . Longitudinal and cross-sectional study of patients with early-onset severe retinal dystrophy associated with RPE65 mutations. Graefes Arch Clin Exp Ophthalmol 2005;243:417-426
CrossRef | Web of Science | Medline4
Thompson DA ,Gyurus P ,Fleischer LL , et al. Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration. Invest Ophthalmol Vis Sci 2000;41:4293-4299
Web of Science | Medline5
Gu SM ,Thompson DA ,Srikumari CR , et al. Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nat Genet 1997;17:194-197
CrossRef | Web of Science | Medline6
Marlhens F ,Bareil C ,Griffoin JM , et al. Mutations in RPE65 cause Leber's congenital amaurosis. Nat Genet 1997;17:139-141
CrossRef | Web of Science | Medline7
Morimura H ,Fishman GA ,Grover SA ,Fulton AB ,Berson EL ,Dryja TP . Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or Leber congenital amaurosis. Proc Natl Acad Sci U S A 1998;95:3088-3093
CrossRef | Web of Science | Medline8
Lotery AJ ,Namperumalsamy P ,Jacobson SG , et al. Mutation analysis of 3 genes in patients with Leber congenital amaurosis. Arch Ophthalmol 2000;118:538-543
Web of Science | Medline9
Thompson DA ,Gal A . Genetic defects in vitamin A metabolism of the retinal pigment epithelium. Dev Ophthalmol 2003;37:141-154
CrossRef | Medline10
Redmond TM ,Yu S ,Lee E , et al. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet 1998;20:344-351
CrossRef | Web of Science | Medline11
Mata NL ,Moghrabi WN ,Lee JS , et al. Rpe65 is a retinyl ester binding protein that presents insoluble substrate to the isomerase in retinal pigment epithelial cells. J Biol Chem 2004;279:635-643
CrossRef | Web of Science | Medline12
Jin M ,Li S ,Moghrabi WN ,Sun H ,Travis GH . Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell 2005;122:449-459
CrossRef | Web of Science | Medline13
Moiseyev G ,Chen Y ,Takahashi Y ,Wu BX ,Ma JX . RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A 2005;102:12413-12418
CrossRef | Web of Science | Medline14
Redmond TM ,Poliakov E ,Yu S ,Tsai JY ,Lu Z ,Gentleman S . Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci U S A 2005;102:13658-13663
CrossRef | Web of Science | Medline15
Znoiko SL ,Crouch RK ,Moiseyev G ,Ma JX . Identification of the RPE65 protein in mammalian cone photoreceptors. Invest Ophthalmol Vis Sci 2002;43:1604-1609
Web of Science | Medline16
Wu BX ,Moiseyev G ,Chen Y ,Rohrer B ,Crouch RK ,Ma JX . Identification of RDH10, an all-trans retinol dehydrogenase, in retinal Muller cells. Invest Ophthalmol Vis Sci 2004;45:3857-3862
CrossRef | Web of Science | Medline17
Veske A ,Nilsson SE ,Narfstrom K ,Gal A . Retinal dystrophy of Swedish Briard/Briard-beagle dogs is due to a 4-bp deletion in RPE65. Genomics 1999;57:57-61
CrossRef | Web of Science | Medline18
Acland GM ,Aguirre GD ,Ray J , et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001;28:92-95
CrossRef | Web of Science | Medline19
Narfstrom K ,Katz ML ,Bragadottir R , et al. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest Ophthalmol Vis Sci 2003;44:1663-1672
CrossRef | Web of Science | Medline20
Narfstrom K ,Katz ML ,Ford M ,Redmond TM ,Rakoczy E ,Bragadottir R . In vivo gene therapy in young and adult RPE65−/− dogs produces long-term visual improvement. J Hered 2003;94:31-37
CrossRef | Web of Science | Medline21
Le Meur G ,Stieger K ,Smith AJ , et al. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 2007;14:292-303
CrossRef | Web of Science | Medline22
Aguirre GK ,Komaromy AM ,Cideciyan AV , et al. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation. PLoS Med 2007;4:e230-e230
CrossRef | Web of Science | Medline23
Gao GP ,Qu G ,Faust LZ , et al. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998;9:2353-2362
CrossRef | Web of Science | Medline24
Auricchio A ,Rolling F . Adeno-associated viral vectors for retinal gene transfer and treatment of retinal diseases. Curr Gene Ther 2005;5:339-348
CrossRef | Web of Science | Medline
- Citing Articles (287)
Citing Articles
1
Crystel Bonnet, Aziz El-Amraoui. (2012) Usher syndrome (sensorineural deafness and retinitis pigmentosa). Current Opinion in Neurology 25:1, 42-49
CrossRef2
Aravind Asokan, David V Schaffer, R Jude Samulski. (2012) The AAV Vector Toolkit: Poised at the Clinical Crossroads. Molecular Therapy
CrossRef3
Frauke Coppieters, Bram De Wilde, Steve Lefever, Ellen De Meester, Nina De Rocker, Caroline Van Cauwenbergh, Filip Pattyn, Françoise Meire, Bart P. Leroy, Jan Hellemans, Jo Vandesompele, Elfride De Baere. (2012) Massively parallel sequencing for early molecular diagnosis in Leber congenital amaurosis. Genetics in Medicine
CrossRef4
Elodie Touchard, Marianne Berdugo, Pascal Bigey, Mohamed El Sanharawi, Michèle Savoldelli, Marie-Christine Naud, Jean-Claude Jeanny, Francine Behar-Cohen. (2012) Suprachoroidal Electrotransfer: A Nonviral Gene Delivery Method to Transfect the Choroid and the Retina Without Detaching the Retina. Molecular Therapy
CrossRef5
S. Herson, F. Hentati, A. Rigolet, A. Behin, N. B. Romero, F. Leturcq, P. Laforet, T. Maisonobe, R. Amouri, H. Haddad, M. Audit, M. Montus, C. Masurier, B. Gjata, C. Georger, M. Cherai, P. Carlier, J.-Y. Hogrel, A. Herson, Y. Allenbach, F. M. Lemoine, D. Klatzmann, H. L. Sweeney, R. C. Mulligan, B. Eymard, D. Caizergues, T. Voit, O. Benveniste. (2012) A phase I trial of adeno-associated virus serotype 1- -sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain
CrossRef6
Rajiv R. Mohan, Jonathan C.K. Tovey, Ajay Sharma, Ashish Tandon. (2012) Gene therapy in the Cornea: 2005–present. Progress in Retinal and Eye Research 31:1, 43-64
CrossRef7
J H McIntosh, M Cochrane, S Cobbold, H Waldmann, S A Nathwani, A M Davidoff, A C Nathwani. (2012) Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Therapy 19:1, 78-85
CrossRef8
H. Steve Zhang, Eunmi Kim, Slgirim Lee, Ik-Sung Ahn, Jae-Hyung Jang. (2012) Transduction of striatum and cortex tissues by adeno-associated viral vectors produced by herpes simplex virus- and baculovirus-based methods. Journal of Virological Methods 179:1, 276-280
CrossRef9
Kevin Gregory-Evans, Kelvin Po, Francis Chang, Cheryl Y. Gregory-Evans. (2012) Pharmacological Enhancement of ex vivo Gene Therapy Neuroprotection in a Rodent Model of Retinal Degeneration. Ophthalmic Research 47:1, 32-38
CrossRef10
Marian M Humphries, Paul F Kenna, Matthew Campbell, Lawrence C S Tam, Anh T H Nguyen, G Jane Farrar, Marina Botto, Anna Sophia Kiang, Peter Humphries. (2012) C1q enhances cone photoreceptor survival in a mouse model of autosomal recessive retinitis pigmentosa. European Journal of Human Genetics 20:1, 64-68
CrossRef11
Christian J. Buchholz, Ralf Sanzenbacher, Silke Schüle. (2012) The European Hospital Exemption Clause—New Option for Gene Therapy?. Human Gene Therapy 23:1, 7-12
CrossRef12
Robert S. Molday, Ulrich Kellner, Bernhard H.F. Weber. (2012) X-linked juvenile retinoschisis: Clinical diagnosis, genetic analysis, and molecular mechanisms. Progress in Retinal and Eye Research
CrossRef13
Yong Liu, Dan Ning Liu, Xiao Hong Meng, Zheng Qin Yin. (2012) Transient Pupillary Light Reflex in Relation to Fundus Autofluorescence and Dark-Adapted Perimetry in Typical Retinitis Pigmentosa. Ophthalmic Research 47:3, 113-121
CrossRef14
Philip D. Kiser, Marcin Golczak, Akiko Maeda, Krzysztof Palczewski. (2012) Key enzymes of the retinoid (visual) cycle in vertebrate retina. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1821:1, 137-151
CrossRef15
James M. Wilson. (2012) It's Time for Gene Therapy to Get Disruptive!. Human Gene Therapy 23:1, 1-3
CrossRef16
Marco A. Zarbin, Carlo Montemagno, James F. Leary, Robert Ritch. (2012) Regenerative nanomedicine and the treatment of degenerative retinal diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 4:1, 113-137
CrossRef17
Yanxiong Mao, Szilard Kiss, Julie L. Boyer, Neil R. Hackett, Jianping Qiu, Andrew Carbone, Jason G. Mezey, Stephen M. Kaminsky, Donald J. D'Amico, Ronald G. Crystal. (2011) Persistent Suppression of Ocular Neovascularization with Intravitreal Administration of AAVrh.10 Coding for Bevacizumab. Human Gene Therapy 22:12, 1525-1535
CrossRef18
C. A. Ku, V. A. Chiodo, S. L. Boye, A. F. X. Goldberg, T. Li, W. W. Hauswirth, V. Ramamurthy. (2011) Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis. Human Molecular Genetics 20:23, 4569-4581
CrossRef19
Mats Hellström, Margaret A. Pollett, Alan R. Harvey. (2011) Post-Injury Delivery of rAAV2-CNTF Combined with Short-Term Pharmacotherapy Is Neuroprotective and Promotes Extensive Axonal Regeneration after Optic Nerve Trauma. Journal of Neurotrauma 28:12, 2475-2483
CrossRef20
Adarsha Koirala, Rasha S. Makkia, Mark J. Cooper, Muna I. Naash. (2011) Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells. Biomaterials 32:35, 9483-9493
CrossRef21
C. Binny, J. McIntosh, M. Della Peruta, H. Kymalainen, E. G. D. Tuddenham, S. M. K. Buckley, S. N. Waddington, J. H. McVey, Y. Spence, C. L. Morton, A. J. Thrasher, J. T. Gray, F. J. Castellino, A. F. Tarantal, A. M. Davidoff, A. C. Nathwani. (2011) AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous haemorrhage. Blood
CrossRef22
A. Bouaita, S. Augustin, C. Lechauve, H. Cwerman-Thibault, P. Benit, M. Simonutti, M. Paques, P. Rustin, J.-A. Sahel, M. Corral-Debrinski. (2011) Downregulation of apoptosis-inducing factor in Harlequin mice induces progressive and severe optic atrophy which is durably prevented by AAV2-AIF1 gene therapy. Brain
CrossRef23
K S Balaggan, Y Duran, A Georgiadis, C Thaung, S E Barker, P K Buch, A MacNeil, S Robbie, J W B Bainbridge, A J Smith, R R Ali. (2011) Absence of ocular malignant transformation after sub-retinal delivery of rAAV2/2 or integrating lentiviral vectors in p53-deficient mice. Gene Therapy
CrossRef24
G J Farrar, S Millington-Ward, N Chadderton, P Humphries, P F Kenna. (2011) Gene-based therapies for dominantly inherited retinopathies. Gene Therapy
CrossRef25
Venki Sundaram, Anthony T. Moore, Robin R. Ali, James W. Bainbridge. (2011) Educational paper. European Journal of Pediatrics
CrossRef26
C-M Lai, M J Estcourt, R P Himbeck, S-Y Lee, I Yew-San Yeo, C Luu, B K Loh, M W Lee, A Barathi, J Villano, C-L Ang, R G van der Most, I J Constable, D Dismuke, R J Samulski, M A Degli-Esposti, E P Rakoczy. (2011) Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Therapy
CrossRef27
Keiko Miyadera, Gregory M. Acland, Gustavo D. Aguirre. (2011) Genetic and phenotypic variations of inherited retinal diseases in dogs: the power of within- and across-breed studies. Mammalian Genome
CrossRef28
Lili Wang, Roberto Calcedo, Peter Bell, Jianping Lin, Rebecca L Grant, Don L Siegel, James M. Wilson. (2011) Impact of Pre-Existing Immunity on Gene Transfer to Nonhuman Primate Liver with Adeno-Associated Virus 8 Vectors. Human Gene Therapy 22:11, 1389-1401
CrossRef29
Slgirim Lee, Jung-Suk Kim, Hun Su Chu, Go-Woon Kim, Jong-In Won, Jae-Hyung Jang. (2011) Electrospun nanofibrous scaffolds for controlled release of adeno-associated viral vectors. Acta Biomaterialia 7:11, 3868-3876
CrossRef30
Samantha L Ginn, Ian E Alexander. (2011) Gene therapy: Progress in childhood disease. Journal of Paediatrics and Child Healthno-no
CrossRef31
Airaj Fasiuddin. (2011) Inherited Retinal Degenerations. International Ophthalmology Clinics 50:4, 45-56
CrossRef32
A J Smith, J W B Bainbridge, R R Ali. (2011) Gene supplementation therapy for recessive forms of inherited retinal dystrophies. Gene Therapy
CrossRef33
L H Vandenberghe, A Auricchio. (2011) Novel adeno-associated viral vectors for retinal gene therapy. Gene Therapy
CrossRef34
V Busskamp, S Picaud, J A Sahel, B Roska. (2011) Optogenetic therapy for retinitis pigmentosa. Gene Therapy
CrossRef35
Sara J Bowne, Marian M Humphries, Lori S Sullivan, Paul F Kenna, Lawrence C S Tam, Anna S Kiang, Matthew Campbell, George M Weinstock, Daniel C Koboldt, Li Ding, Robert S Fulton, Erica J Sodergren, Denis Allman, Sophia Millington-Ward, Arpad Palfi, Alex McKee, Susan H Blanton, Susan Slifer, Ioanna Konidari, G Jane Farrar, Stephen P Daiger, Peter Humphries. (2011) A dominant mutation in RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with choroidal involvement. European Journal of Human Genetics 19:10, 1074-1081
CrossRef36
X. Cao, R. Wei, X. Liu, Y. Zeng, H. Huang, M. Ding, K. Zhang, X.-Y. Liu. (2011) Cancer targeting Gene-Viro-Therapy specific for liver cancer by -fetoprotein-controlled oncolytic adenovirus expression of SOCS3 and IL-24. Acta Biochimica et Biophysica Sinica 43:10, 813-821
CrossRef37
Marc S. Weinberg, Thomas J. McCown. (2011) Current prospects and challenges for epilepsy gene therapy. Experimental Neurology
CrossRef38
Bryan William Jones, Mineo Kondo, Hiroko Terasaki, Carl Brock Watt, Kevin Rapp, James Anderson, Yanhua Lin, Marguerite Victoria Shaw, Jia-Hui Yang, Robert Edward Marc. (2011) Retinal remodeling in the Tg P347L rabbit, a large-eye model of retinal degeneration. The Journal of Comparative Neurology 519:14, 2713-2733
CrossRef39
Marija Mihelec, Rachael A. Pearson, Scott J. Robbie, Prateek K. Buch, Selina A. Azam, James W.B. Bainbridge, Alexander J. Smith, Robin R. Ali. (2011) Long-Term Preservation of Cones and Improvement in Visual Function Following Gene Therapy in a Mouse Model of Leber Congenital Amaurosis Caused by Guanylate Cyclase-1 Deficiency. Human Gene Therapy 22:10, 1179-1190
CrossRef40
Peter Charbel Issa, Robert E MacLaren. (2011) Non-viral retinal gene therapy: a review. Clinical & Experimental Ophthalmologyno-no
CrossRef41
Kristina Narfström, Marilyn Menotti Raymond, Mathias Seeliger. (2011) Characterization of feline hereditary retinal dystrophies using clinical, functional, structural and molecular genetic studies. Veterinary Ophthalmology 14, 30-36
CrossRef42
Eliza Stroh. (2011) Taking the family history in genetic disease. Current Opinion in Ophthalmology 22:5, 340-346
CrossRef43
Richard J. Browning, Helen Mulvana, Mengxing Tang, Jo V. Hajnal, Dominic J. Wells, Robert J. Eckersley. (2011) Influence of Needle Gauge On In Vivo Ultrasound and Microbubble-Mediated Gene Transfection. Ultrasound in Medicine & Biology 37:9, 1531-1537
CrossRef44
Deniz Dalkara, Kathleen D Kolstad, Karen I Guerin, Natalie V Hoffmann, Meike Visel, Ryan R Klimczak, David V Schaffer, John G Flannery. (2011) AAV Mediated GDNF Secretion From Retinal Glia Slows Down Retinal Degeneration in a Rat Model of Retinitis Pigmentosa. Molecular Therapy 19:9, 1602-1608
CrossRef45
Patrick Maier, Marlon R Veldwijk, Frederik Wenz. (2011) Radioprotective gene therapy. Expert Opinion on Biological Therapy 11:9, 1135-1151
CrossRef46
L. S. Carvalho, J. Xu, R. A. Pearson, A. J. Smith, J. W. Bainbridge, L. M. Morris, S. J. Fliesler, X.-Q. Ding, R. R. Ali. (2011) Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Human Molecular Genetics 20:16, 3161-3175
CrossRef47
M Djilas, C Olès, H Lorach, A Bendali, J Dégardin, E Dubus, G Lissorgues-Bazin, L Rousseau, R Benosman, S-H Ieng, S Joucla, B Yvert, P Bergonzo, J Sahel, S Picaud. (2011) Three-dimensional electrode arrays for retinal prostheses: modeling, geometry optimization and experimental validation. Journal of Neural Engineering 8:4, 046020
CrossRef48
James Shorter. 2011. Amyloid Remodeling by Hsp104. , 235-259.
CrossRef49
Joaquin Tosi, Richard J. Davis, Nan-Kai Wang, Matthew Naumann, Chyuan-Sheng Lin, Stephen H. Tsang. (2011) shRNA knockdown of guanylate cyclase 2e or cyclic nucleotide gated channel alpha 1 increases photoreceptor survival in a cGMP phosphodiesterase mouse model of retinitis pigmentosa. Journal of Cellular and Molecular Medicine 15:8, 1778-1787
CrossRef50
Thomas V. Johnson, Natalie D. Bull, Keith R. Martin. (2011) Neurotrophic factor delivery as a protective treatment for glaucoma. Experimental Eye Research 93:2, 196-203
CrossRef51
B Cheng, C Ling, Y Dai, Y Lu, L G Glushakova, S W Y Gee, K E McGoogan, G V Aslanidi, M Park, P W Stacpoole, D Siemann, C Liu, A Srivastava, C Ling. (2011) Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Therapy
CrossRef52
Patricia Favaro, Jonathan D. Finn, Joshua I. Siner, J. Fraser Wright, Katherine A. High, Valder R. Arruda. (2011) Safety of Liver Gene Transfer Following Peripheral Intravascular Delivery of Adeno-Associated Virus (AAV)-5 and AAV-6 in a Large Animal Model. Human Gene Therapy 22:7, 843-852
CrossRef53
Fabian Schmid, Esther Glaus, Daniel Barthelmes, Manfred Fliegauf, Harald Gaspar, Gudrun Nürnberg, Peter Nürnberg, Heymut Omran, Wolfgang Berger, John Neidhardt. (2011) U1 snRNA-mediated gene therapeutic correction of splice defects caused by an exceptionally mild BBS mutation. Human Mutation 32:7, 815-824
CrossRef54
Natalia Caporale, Kathleen D Kolstad, Trevor Lee, Ivan Tochitsky, Deniz Dalkara, Dirk Trauner, Richard Kramer, Yang Dan, Ehud Y Isacoff, John G Flannery. (2011) LiGluR Restores Visual Responses in Rodent Models of Inherited Blindness. Molecular Therapy 19:7, 1212-1219
CrossRef55
K. A. HIGH. (2011) Gene therapy for haemophilia: a long and winding road. Journal of Thrombosis and Haemostasis 9, 2-11
CrossRef56
Lionel Galibert, Otto-Wilhelm Merten. (2011) Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases. Journal of Invertebrate Pathology 107, S80-S93
CrossRef57
M Mehdi Doroudchi, Kenneth P Greenberg, Jianwen Liu, Kimberly A Silka, Edward S Boyden, Jennifer A Lockridge, A Cyrus Arman, Ramesh Janani, Shannon E Boye, Sanford L Boye, Gabriel M Gordon, Benjamin C Matteo, Alapakkam P Sampath, William W Hauswirth, Alan Horsager. (2011) Virally delivered Channelrhodopsin-2 Safely and Effectively Restores Visual Function in Multiple Mouse Models of Blindness. Molecular Therapy 19:7, 1220-1229
CrossRef58
Cédric Boucherie, Jane C Sowden, Robin R Ali. (2011) Induced pluripotent stem cell technology for generating photoreceptors. Regenerative Medicine 6:4, 469-479
CrossRef59
C Mussolino, M della Corte, S Rossi, F Viola, U Di Vicino, E Marrocco, S Neglia, M Doria, F Testa, R Giovannoni, M Crasta, M Giunti, E Villani, M Lavitrano, M L Bacci, R Ratiglia, F Simonelli, A Auricchio, E M Surace. (2011) AAV-mediated photoreceptor transduction of the pig cone-enriched retina. Gene Therapy 18:7, 637-645
CrossRef60
Martin S. Zinkernagel, Paul G. McMenamin, John V. Forrester, Mariapia A. Degli-Esposti. (2011) T cell responses in experimental viral retinitis: Mechanisms, peculiarities and implications for gene therapy with viral vectors. Progress in Retinal and Eye Research 30:4, 275-284
CrossRef61
D. Kampik, R.R. Ali, D.F.P. Larkin. (2011) Experimental gene transfer to the corneal endothelium. Experimental Eye Research
CrossRef62
Hojun Li, Virginia Haurigot, Yannick Doyon, Tianjian Li, Sunnie Y. Wong, Anand S. Bhagwat, Nirav Malani, Xavier M. Anguela, Rajiv Sharma, Lacramiora Ivanciu, Samuel L. Murphy, Jonathan D. Finn, Fayaz R. Khazi, Shangzhen Zhou, David E. Paschon, Edward J. Rebar, Frederic D. Bushman, Philip D. Gregory, Michael C. Holmes, Katherine A. High. (2011) In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475:7355, 217-221
CrossRef63
L. H. Vandenberghe, P. Bell, A. M. Maguire, C. N. Cearley, R. Xiao, R. Calcedo, L. Wang, M. J. Castle, A. C. Maguire, R. Grant, J. H. Wolfe, J. M. Wilson, J. Bennett. (2011) Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in Monkey. Science Translational Medicine 3:88, 88ra54-88ra54
CrossRef64
J-S Kim, H S Chu, K I Park, J-I Won, J-H Jang. (2011) Elastin-like polypeptide matrices for enhancing adeno-associated virus-mediated gene delivery to human neural stem cells. Gene Therapy
CrossRef65
Pernille Hojman, Iben Spanggaard, Caroline Holkman Olsen, Julie Gehl, Hanne Gissel. (2011) Calcium Electrotransfer for Termination of Transgene Expression in Muscle. Human Gene Therapy 22:6, 753-760
CrossRef66
Christopher Evans. (2011) Gene therapy for the regeneration of bone. Injury 42:6, 599-604
CrossRef67
Manzar Ashtari, Laura L. Cyckowski, Justin F. Monroe, Kathleen A. Marshall, Daniel C. Chung, Alberto Auricchio, Francesca Simonelli, Bart P. Leroy, Albert M. Maguire, Kenneth S. Shindler, Jean Bennett. (2011) The human visual cortex responds to gene therapy–mediated recovery of retinal function. Journal of Clinical Investigation 121:6, 2160-2168
CrossRef68
T. Zhang, N. Zhang, W. Baehr, Y. Fu. (2011) Cone opsin determines the time course of cone photoreceptor degeneration in Leber congenital amaurosis. Proceedings of the National Academy of Sciences 108:21, 8879-8884
CrossRef69
Feero, W. Gregory, Guttmacher, Alan E., , Sheffield, Val C., Stone, Edwin M., . (2011) Genomics and the Eye. New England Journal of Medicine 364:20, 1932-1942
Full Text70
Esther Glaus, Fabian Schmid, Romain Da Costa, Wolfgang Berger, John Neidhardt. (2011) Gene Therapeutic Approach Using Mutation-adapted U1 snRNA to Correct a RPGR Splice Defect in Patient-derived Cells. Molecular Therapy 19:5, 936-941
CrossRef71
Barbara Langer, Klaus Cichutek. (2011) Klinische Anwendung der Gentherapie. Bisherige Erfahrungen und Zukunft. Pharmazie in unserer Zeit 40:3, 254-262
CrossRef72
James A. Allay, Susan Sleep, Scott Long, David M. Tillman, Rob Clark, Gael Carney, Paolo Fagone, Jenny H. McIntosh, Arthur W. Nienhuis, Andrew M. Davidoff, Amit C. Nathwani, John T. Gray. (2011) Good Manufacturing Practice Production of Self-Complementary Serotype 8 Adeno-Associated Viral Vector for a Hemophilia B Clinical Trial. Human Gene Therapy 22:5, 595-604
CrossRef73
Mathias Fradot, Volker Busskamp, Valérie Forster, Thérèse Cronin, Thierry Léveillard, Jean Bennett, José-Alain Sahel, Botond Roska, Serge Picaud. (2011) Gene Therapy in Ophthalmology: Validation on Cultured Retinal Cells and Explants from Postmortem Human Eyes. Human Gene Therapy 22:5, 587-593
CrossRef74
Aristides D. Tagalakis, Lin He, Luisa Saraiva, Kenth T. Gustafsson, Stephen L. Hart. (2011) Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. Biomaterials
CrossRef75
Terence R Flotte, Robert M Frederickson, Pedro R Lowenstein, Christian Mueller. (2011) Moving Forward Toward a Cure for Parkinson’s: Neuropathology of the Nigrostriatal Pathway Determines the Location of Growth Factor Delivery. Molecular Therapy 19:5, 827-829
CrossRef76
Federico Mingozzi, Katherine A. High. (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nature Reviews Genetics 12:5, 341-355
CrossRef77
Hildegard Büning. (2011) Gentherapie - Was ist das? “Heilen” mit Genen. Pharmazie in unserer Zeit 40:3, 194-201
CrossRef78
Ian Greener, J. Kevin Donahue. (2011) Gene therapy strategies for cardiac electrical dysfunction. Journal of Molecular and Cellular Cardiology 50:5, 759-765
CrossRef79
Patrik Schatz, Markus Preising, Birgit Lorenz, Birgit Sander, Michael Larsen, Thomas Rosenberg. (2011) Fundus Albipunctatus Associated with Compound Heterozygous Mutations in RPE65. Ophthalmology 118:5, 888-894
CrossRef80
Haoyu Mao, Thomas James, Alison Schwein, Arseniy E. Shabashvili, William W. Hauswirth, Marina S. Gorbatyuk, Alfred S. Lewin. (2011) AAV Delivery of Wild-Type Rhodopsin Preserves Retinal Function in a Mouse Model of Autosomal Dominant Retinitis Pigmentosa. Human Gene Therapy 22:5, 567-575
CrossRef81
Carmine Spampanato, Elvira De Leonibus, Paola Dama, Annagiusi Gargiulo, Alessandro Fraldi, Nicolina Cristina Sorrentino, Fabio Russo, Edoardo Nusco, Alberto Auricchio, Enrico M Surace, Andrea Ballabio. (2011) Efficacy of a Combined Intracerebral and Systemic Gene Delivery Approach for the Treatment of a Severe Lysosomal Storage Disorder. Molecular Therapy 19:5, 860-869
CrossRef82
Jinhui Wang, Susan M. Faust, Joseph E. Rabinowitz. (2011) The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes. Journal of Molecular and Cellular Cardiology 50:5, 793-802
CrossRef83
D. L. Simons, S. L. Boye, W. W. Hauswirth, S. M. Wu. (2011) Gene therapy prevents photoreceptor death and preserves retinal function in a Bardet-Biedl syndrome mouse model. Proceedings of the National Academy of Sciences 108:15, 6276-6281
CrossRef84
Matthew Campbell, Marian M. Humphries, Anna-Sophia Kiang, Anh T. H. Nguyen, Oliviero L. Gobbo, Lawrence C. S. Tam, Mayu Suzuki, Finnian Hanrahan, Ema Ozaki, G.-Jane Farrar, Paul F. Kenna, Peter Humphries. (2011) Systemic low-molecular weight drug delivery to pre-selected neuronal regions. EMBO Molecular Medicine 3:4, 235-245
CrossRef85
Joanne E Sutherland, Megan A Day. (2011) Advantages and disadvantages of molecular testing in ophthalmology. Expert Review of Ophthalmology 6:2, 221-245
CrossRef86
Hélène Cwerman-Thibault, José-Alain Sahel, Marisol Corral-Debrinski. (2011) Mitochondrial medicine: to a new era of gene therapy for mitochondrial DNA mutations. Journal of Inherited Metabolic Disease 34:2, 327-344
CrossRef87
Jingmin Zhou, Xiao Yang, J. Fraser Wright, Katherine A. High, Linda Couto, Guang Qu. (2011) PEG-modulated column chromatography for purification of recombinant adeno-associated virus serotype 9. Journal of Virological Methods 173:1, 99-107
CrossRef88
Dania Qatarneh, Hemal Mehta, Vickie Lee. (2011) Insight into Leber congenital amaurosis: potential for gene therapy. Expert Review of Ophthalmology 6:2, 203-209
CrossRef89
Suzanne MK Buckley, Ahad A Rahim, Jerry KY Chan, Anna L David, Donald M Peebles, Charles Coutelle, Simon N Waddington. (2011) Recent advances in fetal gene therapy. Therapeutic Delivery 2:4, 461-469
CrossRef90
Harry A Quigley. (2011) Glaucoma. The Lancet 377:9774, 1367-1377
CrossRef91
Sophia Millington-Ward, Naomi Chadderton, Mary O'Reilly, Arpad Palfi, Tobias Goldmann, Claire Kilty, Marian Humphries, Uwe Wolfrum, Jean Bennett, Peter Humphries, Paul F Kenna, G Jane Farrar. (2011) Suppression and Replacement Gene Therapy for Autosomal Dominant Disease in a Murine Model of Dominant Retinitis Pigmentosa. Molecular Therapy 19:4, 642-649
CrossRef92
Marinee K. L. Chuah, Inge Petrus, Thierry VandenDriessche. 2011. Gene Therapy for Von Willebrand Disease. , 231-244.
CrossRef93
Anna-Maria Demetriades. (2011) Gene therapy for glaucoma. Current Opinion in Ophthalmology 22:2, 73-77
CrossRef94
G. R. Jayandharan, G. Aslanidi, A. T. Martino, S. C. Jahn, G. Q. Perrin, R. W. Herzog, A. Srivastava. (2011) Activation of the NF- B pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proceedings of the National Academy of Sciences 108:9, 3743-3748
CrossRef95
Claudio Mussolino, Daniela Sanges, Elena Marrocco, Ciro Bonetti, Umberto Di Vicino, Valeria Marigo, Alberto Auricchio, Germana Meroni, Enrico Maria Surace. (2011) Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Molecular Medicine 3:3, 118-128
CrossRef96
Luc JW van der Laan, Yigang Wang, Hugo W Tilanus, Harry LA Janssen, Qiuwei Pan. (2011) AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?. Expert Opinion on Biological Therapy 11:3, 315-327
CrossRef97
Linda Stein, Kamolika Roy, Lei Lei, Shalesh Kaushal. (2011) Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis. Expert Opinion on Biological Therapy 11:3, 429-439
CrossRef98
Rutledge Ellis-Behnke, Jost B. Jonas. (2011) Redefining tissue engineering for nanomedicine in ophthalmology. Acta Ophthalmologica 89:2, e108-e114
CrossRef99
Jane C Sowden, Robin R Ali. (2011) Stem cell therapy for blindness: new developments and implications for the future. Expert Review of Ophthalmology 6:1, 1-3
CrossRef100
Timothy K MacLachlan, Michael Lukason, Margaret Collins, Robert Munger, Elisabete Isenberger, Cindy Rogers, Shana Malatos, Elizabeth DuFresne, James Morris, Roberto Calcedo, Gabor Veres, Abraham Scaria, Laura Andrews, Samuel Wadsworth. (2011) Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular Degeneration. Molecular Therapy 19:2, 326-334
CrossRef101
H Cao, T Yang, X-F Li, J Wu, C Duan, A L Coates, J Hu. (2011) Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression. Gene Therapy 18:2, 173-181
CrossRef102
Michael S D Kormann, Günther Hasenpusch, Manish K Aneja, Gabriela Nica, Andreas W Flemmer, Susanne Herber-Jonat, Marceline Huppmann, Lauren E Mays, Marta Illenyi, Andrea Schams, Matthias Griese, Iris Bittmann, Rupert Handgretinger, Dominik Hartl, Joseph Rosenecker, Carsten Rudolph. (2011) Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nature Biotechnology 29:2, 154-157
CrossRef103
Fred K Chen, Praveen J Patel, Andrew R Webster, Peter J Coffey, Adnan Tufail, Lyndon Da Cruz. (2011) NIDEK MP1 IS ABLE TO DETECT SUBTLE DECLINE IN FUNCTION IN INHERITED AND AGE-RELATED ATROPHIC MACULAR DISEASE WITH STABLE VISUAL ACUITY. Retina 31:2, 371-379
CrossRef104
Gabriele Thumann. (2011) Nonviral gene therapy for age-related macular degeneration. Expert Review of Ophthalmology 6:1, 81-93
CrossRef105
Hilda Petrs-Silva, Astra Dinculescu, Qiuhong Li, Wen-Tao Deng, Ji-jing Pang, Seok-Hong Min, Vince Chiodo, Andy W Neeley, Lakshmanan Govindasamy, Antonette Bennett, Mavis Agbandje-McKenna, Li Zhong, Baozheng Li, Giridhara R Jayandharan, Arun Srivastava, Alfred S Lewin, William W Hauswirth. (2011) Novel Properties of Tyrosine-mutant AAV2 Vectors in the Mouse Retina. Molecular Therapy 19:2, 293-301
CrossRef106
Michael Lukason, Elizabeth DuFresne, Hillard Rubin, Peter Pechan, Qiuhong Li, Ivana Kim, Szilard Kiss, Christina Flaxel, Margaret Collins, Joan Miller, William Hauswirth, Timothy MacLachlan, Samuel Wadsworth, Abraham Scaria. (2011) Inhibition of Choroidal Neovascularization in a Nonhuman Primate Model by Intravitreal Administration of an AAV2 Vector Expressing a Novel Anti-VEGF Molecule. Molecular Therapy 19:2, 260-265
CrossRef107
M G Toscano, Z Romero, P Muñoz, M Cobo, K Benabdellah, F Martin. (2011) Physiological and tissue-specific vectors for treatment of inherited diseases. Gene Therapy 18:2, 117-127
CrossRef108
Daniel X. Hammer. 2011. Advances in Retinal Imaging. , 85-161.
CrossRef109
M J Annear, J T Bartoe, S E Barker, A J Smith, P G Curran, J W Bainbridge, R R Ali, S M Petersen-Jones. (2011) Gene therapy in the second eye of RPE65-deficient dogs improves retinal function. Gene Therapy 18:1, 53-61
CrossRef110
Asier Unciti-Broceta, Loredana Moggio, Kevin Dhaliwal, Laura Pidgeon, Keith Finlayson, Chris Haslett, Mark Bradley. (2011) Safe and efficient in vitro and in vivo gene delivery: tripodal cationic lipids with programmed biodegradability. Journal of Materials Chemistry 21:7, 2154
CrossRef111
S.G. Spain, G. Yaşayan, M. Soliman, F. Heath, A.O. Saeed, C. Alexander. 2011. Nanoparticles for Nucleic Acid Delivery. , 389-410.
CrossRef112
Brian G. Ballios, M. Douglas Baumann, Michael J. Cooke, Molly S. Shoichet. 2011. Central Nervous System. , 1023-1046.
CrossRef113
Huibi Cao, Robert S. Molday, Jim Hu. (2011) Gene therapy: light is finally in the tunnel. Protein & Cell 2:12, 973
CrossRef114
Maria A. Musarella, Ian M. MacDonald. (2011) Current Concepts in the Treatment of Retinitis Pigmentosa. Journal of Ophthalmology 2011, 1-8
CrossRef115
Linda Wu, Simon Lam, Huibi Cao, Rui Guan, Rongqi Duan, Derek van der Kooy, Rod Bremner, Robert S Molday, Jim Hu. (2011) Subretinal gene delivery using helper-dependent adenoviral vectors. Cell & Bioscience 1:1, 15
CrossRef116
J. Bergen, D. Schaffer. 2011. Engineering Viruses For Gene Therapy. , 17-33.
CrossRef117
J. D. Finn, M. C. Ozelo, D. E. Sabatino, H. W. G. Franck, E. P. Merricks, J. M. Crudele, S. Zhou, H. H. Kazazian, D. Lillicrap, T. C. Nichols, V. R. Arruda. (2010) Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 116:26, 5842-5848
CrossRef118
Stylianos Michalakis, Regine Mühlfriedel, Naoyuki Tanimoto, Vidhyasankar Krishnamoorthy, Susanne Koch, M Dominik Fischer, Elvir Becirovic, Lin Bai, Gesine Huber, Susanne C Beck, Edda Fahl, Hildegard Büning, François Paquet-Durand, Xiangang Zong, Tim Gollisch, Martin Biel, Mathias W Seeliger. (2010) Restoration of Cone Vision in the CNGA3−/− Mouse Model of Congenital Complete Lack of Cone Photoreceptor Function. Molecular Therapy 18:12, 2057-2063
CrossRef119
Eyal Banin, Dikla Bandah-Rozenfeld, Alexey Obolensky, Artur V. Cideciyan, Tomas S. Aleman, Devora Marks-Ohana, Malka Sela, Sanford Boye, Alexander Sumaroka, Alejandro J. Roman, Sharon B. Schwartz, William W. Hauswirth, Samuel G. Jacobson, Itzhak Hemo, Dror Sharon. (2010) Molecular Anthropology Meets Genetic Medicine to Treat Blindness in the North African Jewish Population: Human Gene Therapy Initiated in Israel. Human Gene Therapy 21:12, 1749-1757
CrossRef120
David M Markusic, Roland W Herzog, George V Aslanidi, Brad E Hoffman, Baozheng Li, Mengxin Li, Giridhara R. Jayandharan, Chen Ling, Irene Zolotukhin, Wenqin Ma, Sergei Zolotukhin, Arun Srivastava, Li Zhong. (2010) High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed Tyrosines. Molecular Therapy 18:12, 2048-2056
CrossRef121
L. C. S. Tam, A.-S. Kiang, M. Campbell, J. Keaney, G. Jane Farrar, M. M. Humphries, P. F. Kenna, P. Humphries. (2010) Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90). Human Molecular Genetics 19:22, 4421-4436
CrossRef122
Elodie Touchard, Laura Kowalczuk, Carole Bloquel, Marie-Christine Naud, Pascal Bigey, Francine Behar-Cohen. (2010) The ciliary smooth muscle electrotransfer: basic principles and potential for sustained intraocular production of therapeutic proteins. The Journal of Gene Medicine 12:11, 904-919
CrossRef123
David M. Drake, Rahul K. Keswani, Daniel W. Pack. (2010) Effect of Serum on Transfection by Polyethylenimine/Virus-Like Particle Hybrid Gene Delivery Vectors. Pharmaceutical Research 27:11, 2457-2465
CrossRef124
J-H Jang, J T Koerber, K Gujraty, S R Bethi, R S Kane, D V Schaffer. (2010) Surface immobilization of hexa-histidine-tagged adeno-associated viral vectors for localized gene delivery. Gene Therapy 17:11, 1384-1389
CrossRef125
Thomas J. Giove, Miguel Sena-Esteves, William D. Eldred. (2010) Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection. Experimental Eye Research 91:5, 652-659
CrossRef126
Yolanda Diebold, Margarita Calonge. (2010) Applications of nanoparticles in ophthalmology. Progress in Retinal and Eye Research 29:6, 596-609
CrossRef127
Ewelina Betleja, Douglas G. Cole. (2010) Ciliary Trafficking: CEP290 Guards a Gated Community. Current Biology 20:21, R928-R931
CrossRef128
Mengxin Li, Giridhara R. Jayandharan, Baozheng Li, Chen Ling, Wenqin Ma, Arun Srivastava, Li Zhong. (2010) High-Efficiency Transduction of Fibroblasts and Mesenchymal Stem Cells by Tyrosine-Mutant AAV2 Vectors for Their Potential Use in Cellular Therapy. Human Gene Therapy 21:11, 1527-1543
CrossRef129
Mendell, Jerry R., Campbell, Katherine, Rodino-Klapac, Louise, Sahenk, Zarife, Shilling, Chris, Lewis, SarahBowles, Dawn, Gray, Steven, Li, Chengwen, Galloway, Gloria, Malik, Vinod, Coley, Brian, Clark, K. Reed, Li, Juan, Xiao, Xiao, Samulski, Jade, McPhee, Scott W., Samulski, R. Jude, Walker, Christopher M., . (2010) Dystrophin Immunity in Duchenne's Muscular Dystrophy. New England Journal of Medicine 363:15, 1429-1437
Full Text130
Fiona C. Mansergh, Reaz Vawda, Sophia Millington-Ward, Paul F. Kenna, Jochen Haas, Clair Gallagher, John H. Wilson, Peter Humphries, Marius Ader, G. Jane Farrar. (2010) Loss of photoreceptor potential from retinal progenitor cell cultures, despite improvements in survival. Experimental Eye Research 91:4, 500-512
CrossRef131
Linda Hartmann, Kornelia Neveling, Stephanie Borkens, Hildegard Schneider, Marcel Freund, Elke Grassman, Stephan Theiss, Angela Wawer, Stefan Burdach, Arleen D. Auerbach, Detlev Schindler, Helmut Hanenberg, Heiner Schaal. (2010) Correct mRNA Processing at a Mutant TT Splice Donor in FANCC Ameliorates the Clinical Phenotype in Patients and Is Enhanced by Delivery of Suppressor U1 snRNAs. The American Journal of Human Genetics 87:4, 480-493
CrossRef132
Frauke Coppieters, Steve Lefever, Bart P. Leroy, Elfride De Baere. (2010) CEP290, a gene with many faces: mutation overview and presentation of CEP290base. Human Mutation 31:10, 1097-1108
CrossRef133
Luk H. Vandenberghe, Ru Xiao, Martin Lock, Jianping Lin, Michael Korn, James M. Wilson. (2010) Efficient Serotype-Dependent Release of Functional Vector into the Culture Medium During Adeno-Associated Virus Manufacturing. Human Gene Therapy 21:10, 1251-1257
CrossRef134
B. Craige, C.-C. Tsao, D. R. Diener, Y. Hou, K.-F. Lechtreck, J. L. Rosenbaum, G. B. Witman. (2010) CEP290 tethers flagellar transition zone microtubules to the membrane and regulates flagellar protein content. The Journal of Cell Biology 190:5, 927-940
CrossRef135
András M. Komáromy. (2010) Day blind sheep and the importance of large animal disease models. The Veterinary Journal 185:3, 241-242
CrossRef136
Artur V. Cideciyan. (2010) Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Progress in Retinal and Eye Research 29:5, 398-427
CrossRef137
W A Beltran, S L Boye, S E Boye, V A Chiodo, A S Lewin, W W Hauswirth, G D Aguirre. (2010) rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promoters. Gene Therapy 17:9, 1162-1174
CrossRef138
Anneke I. den Hollander, Aaron Black, Jean Bennett, Frans P.M. Cremers. (2010) Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. Journal of Clinical Investigation 120:9, 3042-3053
CrossRef139
M. Ariel Kauss, Laura J. Smith, Li Zhong, Arun Srivastava, K.K. Wong, Saswati Chatterjee. (2010) Enhanced Long-Term Transduction and Multilineage Engraftment of Human Hematopoietic Stem Cells Transduced with Tyrosine-Modified Recombinant Adeno-Associated Virus Serotype 2. Human Gene Therapy 21:9, 1129-1136
CrossRef140
Janka Mátrai, Marinee KL Chuah, Thierry VandenDriessche. (2010) Preclinical and clinical progress in hemophilia gene therapy. Current Opinion in Hematology 17:5, 387-392
CrossRef141
Els Henckaerts, R Michael Linden. (2010) Adeno-associated virus: a key to the human genome?. Future Virology 5:5, 555-574
CrossRef142
Dylan G. Buss, Elizabeth Giuliano, Ajay Sharma, Rajiv R. Mohan. (2010) Gene delivery in the equine cornea: a novel therapeutic strategy. Veterinary Ophthalmology 13:5, 301-306
CrossRef143
Wolfgang Berger, Barbara Kloeckener-Gruissem, John Neidhardt. (2010) The molecular basis of human retinal and vitreoretinal diseases. Progress in Retinal and Eye Research 29:5, 335-375
CrossRef144
Shannon M. Conley, Muna I. Naash. (2010) Nanoparticles for retinal gene therapy. Progress in Retinal and Eye Research 29:5, 376-397
CrossRef145
Andreas Stahl, Lois E.H. Smith. (2010) An eye for discovery. Journal of Clinical Investigation 120:9, 3008-3011
CrossRef146
Natascha K. Schuhmann, Ombretta Pozzoli, Jessica Sallach, Anke Huber, Daniele Avitabile, Luca Perabo, Gunter Rappl, Maurizio C. Capogrossi, Michael Hallek, Maurizio Pesce, Hildegard Büning. (2010) Gene transfer into human cord blood−derived CD34+ cells by adeno-associated viral vectors. Experimental Hematology 38:9, 707-717
CrossRef147
Ajay Sharma, Jonathan C.K. Tovey, Arkasubhra Ghosh, Rajiv R. Mohan. (2010) AAV serotype influences gene transfer in corneal stroma in vivo. Experimental Eye Research 91:3, 440-448
CrossRef148
Colin E Willoughby, Diego Ponzin, Stefano Ferrari, Aires Lobo, Klara Landau, Yadollah Omidi. (2010) Anatomy and physiology of the human eye: effects of mucopolysaccharidoses disease on structure and function - a review. Clinical & Experimental Ophthalmology 38, 2-11
CrossRef149
Rajiv R. Mohan, Rangan Gupta, Maneesh K. Mehan, John W. Cowden, Sunilima Sinha. (2010) Decorin transfection suppresses profibrogenic genes and myofibroblast formation in human corneal fibroblasts. Experimental Eye Research 91:2, 238-245
CrossRef150
Katherine P Ponder, Alberto Auricchio. (2010) Gene therapy for ocular problems in mucopolysaccharidosis: an experimental and promising approach with benefits in animal models - a review. Clinical & Experimental Ophthalmology 38, 43-51
CrossRef151
Kamolika Roy, Linda Stein, Shalesh Kaushal. (2010) Ocular Gene Therapy: An Evaluation of Recombinant Adeno-Associated Virus-Mediated Gene Therapy Interventions for the Treatment of Ocular Disease. Human Gene Therapy 21:8, 915-927
CrossRef152
Basil S. Pawlyk, Oleg V. Bulgakov, Xiaoqing Liu, Xiaoyun Xu, Michael Adamian, Xun Sun, Shahrokh C. Khani, Eliot L. Berson, Michael A. Sandberg, Tiansen Li. (2010) Replacement Gene Therapy with a Human RPGRIP1 Sequence Slows Photoreceptor Degeneration in a Murine Model of Leber Congenital Amaurosis. Human Gene Therapy 21:8, 993-1004
CrossRef153
Olga Kustikova, Martijn Brugman, Christopher Baum. (2010) The genomic risk of somatic gene therapy. Seminars in Cancer Biology 20:4, 269-278
CrossRef154
Xue Cai, Shannon M. Conley, Tong Cheng, Muayyad R. Al-Ubaidi, Muna I. Naash. (2010) A 350 bp region of the proximal promoter of Rds drives cell-type specific gene expression. Experimental Eye Research 91:2, 186-194
CrossRef155
C. Cepko. (2010) Seeing the Light of Day. Science 329:5990, 403-404
CrossRef156
Anthony A Vugler. (2010) PROGRESS TOWARD THE MAINTENANCE AND REPAIR OF DEGENERATING RETINAL CIRCUITRY. Retina 30:7, 983-1001
CrossRef157
J Pang, S E Boye, B Lei, S L Boye, D Everhart, R Ryals, Y Umino, B Rohrer, J Alexander, J Li, X Dai, Q Li, B Chang, R Barlow, W W Hauswirth. (2010) Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. Gene Therapy 17:7, 815-826
CrossRef158
Stephanie Schievenbusch, Ingo Strack, Melanie Scheffler, Roswitha Nischt, Oliver Coutelle, Marianna Hösel, Michael Hallek, Jochen WU Fries, Hans-Peter Dienes, Margarete Odenthal, Hildegard Büning. (2010) Combined Paracrine and Endocrine AAV9 mediated Expression of Hepatocyte Growth Factor for the Treatment of Renal Fibrosis. Molecular Therapy 18:7, 1302-1309
CrossRef159
T Cronin, W Raffelsberger, I Lee-Rivera, C Jaillard, M-L Niepon, B Kinzel, E Clérin, A Petrosian, S Picaud, O Poch, J-A Sahel, T Léveillard. (2010) The disruption of the rod-derived cone viability gene leads to photoreceptor dysfunction and susceptibility to oxidative stress. Cell Death and Differentiation 17:7, 1199-1210
CrossRef160
Barbara Detrick, John J. Hooks. (2010) Immune regulation in the retina. Immunologic Research 47:1-3, 153-161
CrossRef161
B. Lorenz. (2010) Schwerwiegende Netzhauterkrankungen im Kindesalter. Monatsschrift Kinderheilkunde 158:7, 661-668
CrossRef162
A. M. Komaromy, J. J. Alexander, J. S. Rowlan, M. M. Garcia, V. A. Chiodo, A. Kaya, J. C. Tanaka, G. M. Acland, W. W. Hauswirth, G. D. Aguirre. (2010) Gene therapy rescues cone function in congenital achromatopsia. Human Molecular Genetics 19:13, 2581-2593
CrossRef163
Katherine A. High, J. Fraser Wright. 2010. Gene Therapy Trials in Hemophilia A and B. , 231-238.
CrossRef164
V. R. Arruda, H. H. Stedman, V. Haurigot, G. Buchlis, S. Baila, P. Favaro, Y. Chen, H. G. Franck, S. Zhou, J. F. Wright, L. B. Couto, H. Jiang, G. F. Pierce, D. A. Bellinger, F. Mingozzi, T. C. Nichols, K. A. High. (2010) Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood 115:23, 4678-4688
CrossRef165
Elsa Lhériteau, Lyse Libeau, Alexandra Mendes-Madeira, Jack-Yves Deschamps, Michel Weber, Guylène Le Meur, Nathalie Provost, Caroline Guihal, Philippe Moullier, Fabienne Rolling. (2010) Regulation of Retinal Function but Nonrescue of Vision in RPE65-deficient Dogs Treated With Doxycycline-regulatable AAV Vectors. Molecular Therapy 18:6, 1085-1093
CrossRef166
Alexa N. Bramall, Alan F. Wright, Samuel G. Jacobson, Roderick R. McInnes. (2010) The Genomic, Biochemical, and Cellular Responses of the Retina in Inherited Photoreceptor Degenerations and Prospects for the Treatment of These Disorders. Annual Review of Neuroscience 33:1, 441-472
CrossRef167
Gabriel Nistor, Magdalene J. Seiler, Fengrong Yan, David Ferguson, Hans S. Keirstead. (2010) Three-dimensional early retinal progenitor 3D tissue constructs derived from human embryonic stem cells. Journal of Neuroscience Methods 190:1, 63-70
CrossRef168
Jon P Connelly, Jenny C Barker, Shondra Pruett-Miller, Matthew H Porteus. (2010) Gene Correction by Homologous Recombination With Zinc Finger Nucleases in Primary Cells From a Mouse Model of a Generic Recessive Genetic Disease. Molecular Therapy 18:6, 1103-1110
CrossRef169
H. Burton, C. Alberg, A. T. Moore. (2010) Genetics in ophthalmology: equity in service provision?. Journal of Public Health 32:2, 259-266
CrossRef170
Fansheng Kong, Wensheng Li, Xia Li, Qinxiang Zheng, Xufeng Dai, Xiangtian Zhou, Sanford L. Boye, William W. Hauswirth, Jia Qu, Ji-jing Pang. (2010) Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse. Experimental Eye Research 90:5, 546-554
CrossRef171
Stewart Thompson, Rebecca E. H. Whiting, Randy H. Kardon, Edwin M. Stone, Kristina Narfström. (2010) Effects of hereditary retinal degeneration due to a CEP290 mutation on the feline pupillary light reflex. Veterinary Ophthalmology 13:3, 151-157
CrossRef172
Kathleen D. Kolstad, Deniz Dalkara, Karen Guerin, Meike Visel, Natalie Hoffmann, David V. Schaffer, John G. Flannery. (2010) Changes in Adeno-Associated Virus-Mediated Gene Delivery in Retinal Degeneration. Human Gene Therapy 21:5, 571-578
CrossRef173
T. Leveillard, J. A. Sahel. (2010) Rod-Derived Cone Viability Factor for Treating Blinding Diseases: From Clinic to Redox Signaling. Science Translational Medicine 2:26, 26ps16-26ps16
CrossRef174
Matthew RJ Mason, Erich ME Ehlert, Ruben Eggers, Chris W Pool, Stephan Hermening, Angelina Huseinovic, Eric Timmermans, Bas Blits, Joost Verhaagen. (2010) Comparison of AAV Serotypes for Gene Delivery to Dorsal Root Ganglion Neurons. Molecular Therapy 18:4, 715-724
CrossRef175
Andreas S Beutler. (2010) AAV Provides an Alternative for Gene Therapy of the Peripheral Sensory Nervous System. Molecular Therapy 18:4, 670-673
CrossRef176
E Ayuso, F Mingozzi, J Montane, X Leon, X M Anguela, V Haurigot, S A Edmonson, L Africa, S Zhou, K A High, F Bosch, J F Wright. (2010) High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Therapy 17:4, 503-510
CrossRef177
Mehrdad Rafat, Carolyne A. Cléroux, Wai Gin Fong, Adam N. Baker, Brian C. Leonard, Michael D. O'Connor, Catherine Tsilfidis. (2010) PEG–PLA microparticles for encapsulation and delivery of Tat-EGFP to retinal cells. Biomaterials 31:12, 3414-3421
CrossRef178
A Georgiadis, M Tschernutter, J W B Bainbridge, S J Robbie, J McIntosh, A C Nathwani, A J Smith, R R Ali. (2010) AAV-mediated knockdown of Peripherin-2 in vivo using miRNA-based hairpins. Gene Therapy 17:4, 486-493
CrossRef179
E. A. O'Toole. 2010. Molecular Biology. , 1-22.
CrossRef180
D. Amado, F. Mingozzi, D. Hui, J. L. Bennicelli, Z. Wei, Y. Chen, E. Bote, R. L. Grant, J. A. Golden, K. Narfstrom, N. A. Syed, S. E. Orlin, K. A. High, A. M. Maguire, J. Bennett. (2010) Safety and Efficacy of Subretinal Readministration of a Viral Vector in Large Animals to Treat Congenital Blindness. Science Translational Medicine 2:21, 21ra16-21ra16
CrossRef181
Florian Kreppel. (2010) AAV-2: how can the capsid be modified to improve the viral vector in gene therapy?. Future Virology 5:2, 133-135
CrossRef182
S Nayak, R W Herzog. (2010) Progress and prospects: immune responses to viral vectors. Gene Therapy 17:3, 295-304
CrossRef183
Francesca Simonelli, Albert M Maguire, Francesco Testa, Eric A Pierce, Federico Mingozzi, Jeannette L Bennicelli, Settimio Rossi, Kathleen Marshall, Sandro Banfi, Enrico M Surace, Junwei Sun, T Michael Redmond, Xiaosong Zhu, Kenneth S Shindler, Gui-Shuang Ying, Carmela Ziviello, Carmela Acerra, J Fraser Wright, Jennifer Wellman McDonnell, Katherine A High, Jean Bennett, Alberto Auricchio. (2010) Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration. Molecular Therapy 18:3, 643-650
CrossRef184
Arpad Palfi, Sophia Millington-Ward, Naomi Chadderton, Mary O'Reilly, Tobias Goldmann, Marian M. Humphries, Tiansen Li, Uwe Wolfrum, Peter Humphries, Paul F. Kenna, G. Jane Farrar. (2010) Adeno-Associated Virus-Mediated Rhodopsin Replacement Provides Therapeutic Benefit in Mice with a Targeted Disruption of the Rhodopsin Gene. Human Gene Therapy 21:3, 311-323
CrossRef185
Christian K. Schneider, Paula Salmikangas, Bernd Jilma, Bruno Flamion, Lyubina Racheva Todorova, Anna Paphitou, Ivana Haunerova, Toivo Maimets, Jean-Hugues Trouvin, Egbert Flory, Asterios Tsiftsoglou, Balázs Sarkadi, Kolbeinn Gudmundsson, Maura O'Donovan, Giovanni Migliaccio, Jānis Ancāns, Romaldas Mačiulaitis, Jean-Louis Robert, Anthony Samuel, Johannes H. Ovelgönne, Marit Hystad, Andrzej Mariusz Fal, Beatriz Silva Lima, Anca Stela Moraru, Peter Turčáni, Robert Zorec, Sol Ruiz, Lennart Åkerblom, Gopalan Narayanan, Alastair Kent, Fabrizia Bignami, J. George Dickson, Dietger Niederwieser, María-Angeles Figuerola-Santos, Ilona G. Reischl, Claire Beuneu, Rosen Georgiev, Maria Vassiliou, Alena Pychova, Mette Clausen, Taina Methuen, Sophie Lucas, Martina Schüssler-Lenz, Vasilios Kokkas, Zsuzsanna Buzás, Niall MacAleenan, Maria Cristina Galli, Aija Linē, Jolanta Gulbinovic, Guy Berchem, Mariusz Frączek, Margarida Menezes-Ferreira, Nela Vilceanu, Mikuláš Hrubiško, Petra Marinko, Marcos Timón, Wing Cheng, George Andrew Crosbie, Nick Meade, Michelino Lipucci di Paola, Thierry VandenDriessche, Per Ljungman, Lucia D'Apote, Olga Oliver-Diaz, Isabel Büttel, Patrick Celis. (2010) Challenges with advanced therapy medicinal products and how to meet them. Nature Reviews Drug Discovery 9:3, 195-201
CrossRef186
Stephen L. Hart. (2010) Multifunctional nanocomplexes for gene transfer and gene therapy. Cell Biology and Toxicology 26:1, 69-81
CrossRef187
James Acheson. (2010) Blindness in neurological disease: a short overview of new therapies from translational research. Current Opinion in Neurology 23:1, 1-3
CrossRef188
Fulvio Mavilio. (2010) Gene therapy: back on track?. EMBO reports 11:2, 75-75
CrossRef189
Shay Reicher, Eyal Seroussi, Elisha Gootwine. (2010) A mutation in gene CNGA3 is associated with day blindness in sheep. Genomics 95:2, 101-104
CrossRef190
Ajay Sharma, Arkasubhra Ghosh, Eric T. Hansen, Jason M. Newman, Rajiv R. Mohan. (2010) Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblasts. Brain Research Bulletin 81:2-3, 273-278
CrossRef191
Yusuke Murakami, Yasuhiro Ikeda, Yoshikazu Yonemitsu, Masanori Miyazaki, Makoto Inoue, Mamoru Hasegawa, Katsuo Sueishi, Tatsuro Ishibashi. (2010) Inhibition of Choroidal Neovascularization via Brief Subretinal Exposure to a Newly Developed Lentiviral Vector Pseudotyped with Sendai Viral Envelope Proteins. Human Gene Therapy 21:2, 199-209
CrossRef192
Shilpa Vashist, Mimi Cushman, James Shorter. (2010) Applying Hsp104 to protein-misfolding disordersThis paper is one of a selection of papers published in this special issue entitled 8th International Conference on AAA Proteins and has undergone the Journal's usual peer review process.. Biochemistry and Cell Biology 88:1, 1-13
CrossRef193
Jaan Toelen, Jan Deprest. (2010) A Ray of Light for Fetal Therapy. Human Gene Therapy 21:2, 137-139
CrossRef194
Arlene V. Drack, Scott R. Lambert, Edwin M. Stone. (2010) From the Laboratory to the Clinic: Molecular Genetic Testing in Pediatric Ophthalmology. American Journal of Ophthalmology 149:1, 10-17.e2
CrossRef195
Eric A Pierce. 2010. Retinitis pigmentosa and related disorders. , 579-589.
CrossRef196
Yunkou Wu, Christiane E. Carney, Michael Denton, Elaine Hart, Piyu Zhao, Daniel N. Streblow, A. Dean Sherry, Mark Woods. (2010) Polymeric PARACEST MRI contrast agents as potential reporters for gene therapy. Organic & Biomolecular Chemistry 8:23, 5333
CrossRef197
Zhijian Wu, Hongyan Yang, Peter Colosi. (2010) Effect of Genome Size on AAV Vector Packaging. Molecular Therapy 18:1, 80-86
CrossRef198
Lili Wang, Roberto Calcedo, Huan Wang, Peter Bell, Rebecca Grant, Luk H Vandenberghe, Julio Sanmiguel, Hiroki Morizono, Mark L Batshaw, James M Wilson. (2010) The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques. Molecular Therapy 18:1, 126-134
CrossRef199
Muhammad Ali Memon, Joseph F Rizzo. 2010. Visual prostheses and other assistive devices. , 590-598.
CrossRef200
E. A. O'Toole, J. E. Mellerio. 2010. , 1.
CrossRef201
Jonathan D Finn, Daniel Hui, Harre D Downey, Danielle Dunn, Gary C Pien, Federico Mingozzi, Shangzhen Zhou, Katherine A High. (2010) Proteasome Inhibitors Decrease AAV2 Capsid derived Peptide Epitope Presentation on MHC Class I Following Transduction. Molecular Therapy 18:1, 135-142
CrossRef202
X Sun, B Pawlyk, X Xu, X Liu, O V Bulgakov, M Adamian, M A Sandberg, S C Khani, M-H Tan, A J Smith, R R Ali, T Li. (2010) Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Therapy 17:1, 117-131
CrossRef203
Yi Lai, Yongping Yue, Dongsheng Duan. (2010) Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb. Molecular Therapy 18:1, 75-79
CrossRef204
James T Koerber, Ryan Klimczak, Jae-Hyung Jang, Deniz Dalkara, John G Flannery, David V Schaffer. (2009) Molecular Evolution of Adeno-associated Virus for Enhanced Glial Gene Delivery. Molecular Therapy 17:12, 2088-2095
CrossRef205
M. Klein, D. G. Birch. (2009) Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST). Documenta Ophthalmologica 119:3, 217-224
CrossRef206
Keryn A Williams, Douglas J Coster. (2009) Gene therapy for diseases of the cornea â a review. Clinical & Experimental Ophthalmology
CrossRef207
Elias I. Traboulsi. (2009) Hope and major strides for genetic diseases of the eye. Journal of Genetics 88:4, 395-397
CrossRef208
Daniel C. Chung, Elias I. Traboulsi. (2009) Leber congenital amaurosis: Clinical correlations with genotypes, gene therapy trials update, and future directions. Journal of American Association for Pediatric Ophthalmology and Strabismus 13:6, 587-592
CrossRef209
Hiroshi Tomita, Eriko Sugano, Hitomi Isago, Makoto Tamai. (2009) Channelrhodopsins provide a breakthrough insight into strategies for curing blindness. Journal of Genetics 88:4, 409-415
CrossRef210
Christopher B Doering, H Trent Spencer. (2009) Advancements in gene transfer-based therapy for hemophilia A. Expert Review of Hematology 2:6, 673-683
CrossRef211
Albert M Maguire, Katherine A High, Alberto Auricchio, J Fraser Wright, Eric A Pierce, Francesco Testa, Federico Mingozzi, Jeannette L Bennicelli, Gui-shuang Ying, Settimio Rossi, Ann Fulton, Kathleen A Marshall, Sandro Banfi, Daniel C Chung, Jessica IW Morgan, Bernd Hauck, Olga Zelenaia, Xiaosong Zhu, Leslie Raffini, Frauke Coppieters, Elfride De Baere, Kenneth S Shindler, Nicholas J Volpe, Enrico M Surace, Carmela Acerra, Arkady Lyubarsky, T Michael Redmond, Edwin Stone, Junwei Sun, Jennifer Wellman McDonnell, Bart P Leroy, Francesca Simonelli, Jean Bennett. (2009) Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. The Lancet 374:9701, 1597-1605
CrossRef212
Thierry VandenDriessche. (2009) Gene Therapy Delivers. Human Gene Therapy 20:11, 1222-1223
CrossRef213
Frans PM Cremers, Rob WJ Collin. (2009) Promises and challenges of genetic therapy for blindness. The Lancet 374:9701, 1569-1570
CrossRef214
Pedro R Lowenstein. (2009) Risk in Clinical Research: Size Matters!. Molecular Therapy 17:11, 1833-1834
CrossRef215
Thomas Ritter, Uwe Pleyer. (2009) Novel gene therapeutic strategies for the induction of tolerance in cornea transplantation. Expert Review of Clinical Immunology 5:6, 749-764
CrossRef216
Carla B. Mellough, David H.W. Steel, Majlinda Lako. (2009) Genetic Basis of Inherited Macular Dystrophies and Implications for Stem Cell Therapy. Stem Cells 27:11, 2833-2845
CrossRef217
M. Campbell, A. T. H. Nguyen, A.-S. Kiang, L. C. S. Tam, O. L. Gobbo, C. Kerskens, S. N. Dhubhghaill, M. M. Humphries, G.-J. Farrar, P. F. Kenna, P. Humphries. (2009) An experimental platform for systemic drug delivery to the retina. Proceedings of the National Academy of Sciences 106:42, 17817-17822
CrossRef218
K A Williams, H M Brereton, D J Coster. (2009) Prospects for genetic modulation of corneal graft survival. Eye 23:10, 1904-1909
CrossRef219
J W B Bainbridge. (2009) Prospects for gene therapy of inherited retinal disease. Eye 23:10, 1898-1903
CrossRef220
Peter Walter. (2009) Implants for artificial vision. Expert Review of Ophthalmology 4:5, 515-523
CrossRef221
David A Mackey, Jane R MacKinnon, Shayne A Brown, Lisa S Kearns, Jonathan B Ruddle, Paul G Sanfilippo, Cong Sun, Christopher J Hammond, Terri L Young, Nicholas G Martin, Alex W Hewitt. (2009) Twins Eye Study in Tasmania (TEST): Rationale and Methodology to Recruit and Examine Twins. Twin Research and Human Genetics 12:5, 441-454
CrossRef222
F. Mingozzi, J. J. Meulenberg, D. J. Hui, E. Basner-Tschakarjan, N. C. Hasbrouck, S. A. Edmonson, N. A. Hutnick, M. R. Betts, J. J. Kastelein, E. S. Stroes, K. A. High. (2009) AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114:10, 2077-2086
CrossRef223
Stefanie Ebert, Karin Weigelt, Yana Walczak, Wolfgang Drobnik, Richard Mauerer, David A. Hume, Bernhard H. F. Weber, Thomas Langmann. (2009) Docosahexaenoic acid attenuates microglial activation and delays early retinal degeneration. Journal of Neurochemistry 110:6, 1863-1875
CrossRef224
Artur V. Cideciyan, William W. Hauswirth, Tomas S. Aleman, Shalesh Kaushal, Sharon B. Schwartz, Sanford L. Boye, Elizabeth A.M. Windsor, Thomas J. Conlon, Alexander Sumaroka, Ji-jing Pang, Alejandro J. Roman, Barry J. Byrne, Samuel G. Jacobson. (2009) Human RPE65 Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year. Human Gene Therapy 20:9, 999-1004
CrossRef225
Monika Pradhan, Ian Hayes, Andrea Vincent. (2009) An audit of genetic testing in diagnosis of inherited retinal disorders: a prerequisite for gene-specific intervention. Clinical & Experimental Ophthalmology 37:7, 703-711
CrossRef226
Joanne E Sutherland, Megan A Day. (2009) Genetic counseling and genetic testing in ophthalmology. Current Opinion in Ophthalmology 20:5, 343-350
CrossRef227
Yasuhiro Ikeda, Yoshikazu Yonemitsu, Masanori Miyazaki, Ri-ichiro Kohno, Yusuke Murakami, Toshinori Murata, Yoshinobu Goto, Toshiaki Tabata, Yasuji Ueda, Fumiko Ono, Toshimichi Suzuki, Naohide Ageyama, Keiji Terao, Mamoru Hasegawa, Katsuo Sueishi, Tatsuro Ishibashi. (2009) Acute Toxicity Study of a Simian Immunodeficiency Virus-Based Lentiviral Vector for Retinal Gene Transfer in Nonhuman Primates. Human Gene Therapy 20:9, 943-954
CrossRef228
Valder R Arruda, Patricia Favaro, Jonathan D Finn. (2009) Strategies to Modulate Immune Responses: A New Frontier for Gene Therapy. Molecular Therapy 17:9, 1492-1503
CrossRef229
Daniel C Chung, Vivian Lee, Albert M Maguire. (2009) Recent advances in ocular gene therapy. Current Opinion in Ophthalmology 20:5, 377-381
CrossRef230
(2009) The Digest. Human Gene Therapy 20:9, 920-920
CrossRef231
T. VandenDriessche, Z. Ivics, Z. Izsvak, M. K. L. Chuah. (2009) Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood 114:8, 1461-1468
CrossRef232
Cideciyan, Artur V., , Hauswirth, William W., , Aleman, Tomas S., , Kaushal, Shalesh, , Schwartz, Sharon B., , Boye, Sanford L., , Windsor, Elizabeth A.M., , Conlon, Thomas J., , Sumaroka, Alexander, Roman, Alejandro J., , Byrne, Barry J., , Jacobson, Samuel G., . (2009) Vision 1 Year after Gene Therapy for Leber's Congenital Amaurosis. New England Journal of Medicine 361:7, 725-727
Full Text233
Annagiusi Gargiulo, Ciro Bonetti, Sandro Montefusco, Simona Neglia, Umberto Di Vicino, Elena Marrocco, Michele Della Corte, Luciano Domenici, Alberto Auricchio, Enrico M Surace. (2009) AAV-mediated Tyrosinase Gene Transfer Restores Melanogenesis and Retinal Function in a Model of Oculo-cutaneous Albinism Type I (OCA1). Molecular Therapy 17:8, 1347-1354
CrossRef234
James I. Geller, Timothy P. Cripe. (2009) Adenovirus gene therapy for pediatric cancers: Shall we gather at the liver?. Pediatric Blood & Cancer 53:2, 133-135
CrossRef235
Kim Van Vliet, Yasmin Mohiuddin, Scott McClung, Veronique Blouin, Fabienne Rolling, Philippe Moullier, Mavis Agbandje-McKenna, Richard O. Snyder. (2009) Adeno-associated virus capsid serotype identification: Analytical methods development and application. Journal of Virological Methods 159:2, 167-177
CrossRef236
Heather Thomson, Andrew Lotery. (2009) The promise of nanomedicine for ocular disease. Nanomedicine 4:6, 599-604
CrossRef237
Anna M. Wagner, Andreina Schoeberlein, Daniel Surbek. (2009) Fetal gene therapy: Opportunities and risks. Advanced Drug Delivery Reviews 61:10, 813-821
CrossRef238
Klaus Wanisch, Rafael J Yáñez-Muñoz. (2009) Integration-deficient Lentiviral Vectors: A Slow Coming of Age. Molecular Therapy 17:8, 1316-1332
CrossRef239
T K Park, Z Wu, S Kjellstrom, Y Zeng, R A Bush, P A Sieving, P Colosi. (2009) Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Therapy 16:7, 916-926
CrossRef240
Xuyang Liu, Carol A. Rasmussen, B'Ann T. Gabelt, Curtis R. Brandt, Paul L. Kaufman. (2009) Gene Therapy Targeting Glaucoma: Where Are We?. Survey of Ophthalmology 54:4, 472-486
CrossRef241
M. H. Tan, A. J. Smith, B. Pawlyk, X. Xu, X. Liu, J. B. Bainbridge, M. Basche, J. McIntosh, H. V. Tran, A. Nathwani, T. Li, R. R. Ali. (2009) Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors. Human Molecular Genetics 18:12, 2099-2114
CrossRef242
T. Maeda, A. V. Cideciyan, A. Maeda, M. Golczak, T. S. Aleman, S. G. Jacobson, K. Palczewski. (2009) Loss of cone photoreceptors caused by chromophore depletion is partially prevented by the artificial chromophore pro-drug, 9-cis-retinyl acetate. Human Molecular Genetics 18:12, 2277-2287
CrossRef243
Edwin M Stone. (2009) Progress toward effective treatments for human photoreceptor degenerations. Current Opinion in Genetics & Development 19:3, 283-289
CrossRef244
Susie E. Barker, Cathryn A. Broderick, Scott J. Robbie, Yanai Duran, Mythili Natkunarajah, Prateek Buch, Kamaljit S. Balaggan, Robert E. MacLaren, James W. B. Bainbridge, Alexander J. Smith, Robin R. Ali. (2009) Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice. The Journal of Gene Medicine 11:6, 486-497
CrossRef245
Bo Hai, Xing Yan, Antonis Voutetakis, Changyu Zheng, Ana P. Cotrim, Zhaochen Shan, Gang Ding, Chunmei Zhang, Junji Xu, Corinne M. Goldsmith, Sandra Afione, John A. Chiorini, Bruce J. Baum, Songlin Wang. (2009) Long-term transduction of miniature pig parotid glands using serotype 2 adeno-associated viral vectors. The Journal of Gene Medicine 11:6, 506-514
CrossRef246
Jonathan L Tobin, Philip L Beales. (2009) The nonmotile ciliopathies. Genetics in Medicine 11:6, 386-402
CrossRef247
Yasuhiro Ikeda, Yoshikazu Yonemitsu, Masanori Miyazaki, Ri-ichiro Kohno, Yusuke Murakami, Toshinori Murata, Toshiaki Tabata, Yasuji Ueda, Fumiko Ono, Toshimichi Suzuki, Naohide Ageyama, Keiji Terao, Mamoru Hasegawa, Katsuo Sueishi, Tatsuro Ishibashi. (2009) Stable Retinal Gene Expression in Nonhuman Primates via Subretinal Injection of SIVagm-Based Lentiviral Vectors. Human Gene Therapy 20:6, 573-579
CrossRef248
J. M. Wilson. (2009) A History Lesson for Stem Cells. Science 324:5928, 727-728
CrossRef249
Ying Yang, Saddek Mohand-Said, Aude Danan, Manuel Simonutti, Valérie Fontaine, Emmanuelle Clerin, Serge Picaud, Thierry Léveillard, José-Alain Sahel. (2009) Functional Cone Rescue by RdCVF Protein in a Dominant Model of Retinitis Pigmentosa. Molecular Therapy 17:5, 787-795
CrossRef250
William A. Beltran. (2009) The use of canine models of inherited retinal degeneration to test novel therapeutic approaches. Veterinary Ophthalmology 12:3, 192-204
CrossRef251
Alexander J. Smith, James W. Bainbridge, Robin R. Ali. (2009) Prospects for retinal gene replacement therapy. Trends in Genetics 25:4, 156-165
CrossRef252
M Hellström, M J Ruitenberg, M A Pollett, E M E Ehlert, J Twisk, J Verhaagen, A R Harvey. (2009) Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection. Gene Therapy 16:4, 521-532
CrossRef253
M.A. Gamulescu, A.B. Renner, H. Helbig. (2009) Klinische Manifestationen von Funktionsstörungen des retinalen Pigmentepithels. Der Ophthalmologe 106:4, 305-310
CrossRef254
Naomi Chadderton, Sophia Millington-Ward, Arpad Palfi, Mary O'Reilly, Gearóid Tuohy, Marian M Humphries, Tiansen Li, Peter Humphries, Paul F Kenna, G Jane Farrar. (2009) Improved Retinal Function in a Mouse Model of Dominant Retinitis Pigmentosa Following AAV-delivered Gene Therapy. Molecular Therapy 17:4, 593-599
CrossRef255
A S Beutler, M Reinhardt. (2009) AAV for pain: steps towards clinical translation. Gene Therapy 16:4, 461-469
CrossRef256
Hilda Petrs-Silva, Astra Dinculescu, Qiuhong Li, Seok-Hong Min, Vince Chiodo, Ji-Jing Pang, Li Zhong, Sergei Zolotukhin, Arun Srivastava, Alfred S Lewin, William W Hauswirth. (2009) High-efficiency Transduction of the Mouse Retina by Tyrosine-mutant AAV Serotype Vectors. Molecular Therapy 17:3, 463-471
CrossRef257
L H Vandenberghe, J M Wilson, G Gao. (2009) Tailoring the AAV vector capsid for gene therapy. Gene Therapy 16:3, 311-319
CrossRef258
Knut Stieger, Josef Schroeder, Nathalie Provost, Alexandra Mendes-Madeira, Brahim Belbellaa, Guylène Le Meur, Michel Weber, Jack-Yves Deschamps, Birgit Lorenz, Philippe Moullier, Fabienne Rolling. (2009) Detection of Intact rAAV Particles up to 6 Years After Successful Gene Transfer in the Retina of Dogs and Primates. Molecular Therapy 17:3, 516-523
CrossRef259
Rangeetha Naik, Arijit Mukhopadhyay, Munia Ganguli. (2009) Gene delivery to the retina: focus on non-viral approaches. Drug Discovery Today 14:5-6, 306-315
CrossRef260
(2009) Ocular Genetics and down Syndrome. Journal of Pediatric Ophthalmology & Strabismus 46:2, 75-75
CrossRef261
R. C. Carlisle, Y. Di, A. M. Cerny, A. F.-P. Sonnen, R. B. Sim, N. K. Green, V. Subr, K. Ulbrich, R. J. C. Gilbert, K. D. Fisher, R. W. Finberg, L. W. Seymour. (2009) Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113:9, 1909-1918
CrossRef262
Gaby Tanner, Esther Glaus, Daniel Barthelmes, Marius Ader, Johannes Fleischhauer, Franco Pagani, Wolfgang Berger, John Neidhardt. (2009) Therapeutic strategy to rescue mutation-induced exon skipping in rhodopsin by adaptation of U1 snRNA. Human Mutation 30:2, 255-263
CrossRef263
Sarah Catherine Borrie, James Duggan, M Francesca Cordeiro. (2009) Retinal cell apoptosis. Expert Review of Ophthalmology 4:1, 27-45
CrossRef264
M. Goralska, J. Ferrell, J. Harned, M. Lall, S. Nagar, L.N. Fleisher, M.C. McGahan. (2009) Iron metabolism in the eye: A review. Experimental Eye Research 88:2, 204-215
CrossRef265
B. Wissinger. (2009) Zapfendystrophien – von der Bedeutsamkeit einer Minderheit von Photorezeptoren. Der Ophthalmologe 106:2, 97-98
CrossRef266
M. Samardzija, N. Tanimoto, C. Kostic, S. Beck, V. Oberhauser, S. Joly, M. Thiersch, E. Fahl, Y. Arsenijevic, J. von Lintig, A. Wenzel, M. W. Seeliger, C. Grimm. (2009) In conditions of limited chromophore supply rods entrap 11-cis-retinal leading to loss of cone function and cell death. Human Molecular Genetics 18:7, 1266-1275
CrossRef267
Pasqualina Colella, Gabriella Cotugno, Alberto Auricchio. (2009) Ocular gene therapy: current progress and future prospects. Trends in Molecular Medicine 15:1, 23-31
CrossRef268
Te-Lang Wu, Hildegund C.J. Ertl. (2009) Immune barriers to successful gene therapy. Trends in Molecular Medicine 15:1, 32-39
CrossRef269
Xue Cai, Shannon M. Conley, Muna I. Naash. (2009) RPE65: Role in the Visual Cycle, Human Retinal Disease, and Gene Therapy. Ophthalmic Genetics 30:2, 57-62
CrossRef270
Khalil N Abi-Nader, Charles H Rodeck, Anna L David. (2009) Prenatal gene therapy for the early treatment of genetic disorders. Expert Review of Obstetrics & Gynecology 4:1, 25-44
CrossRef271
Javier Sancho-Pelluz, Blanca Arango-Gonzalez, Stefan Kustermann, Francisco Javier Romero, Theo Veen, Eberhart Zrenner, Per Ekström, François Paquet-Durand. (2008) Photoreceptor Cell Death Mechanisms in Inherited Retinal Degeneration. Molecular Neurobiology 38:3, 253-269
CrossRef272
Marisol Corral-Debrinski, José-Alain Sahel. (2008) Focus on optic neuropathies due to mitochondrial dysfunction: molecular bases and putative therapies. Expert Review of Ophthalmology 3:6, 599-603
CrossRef273
James W. Yockman, Andrew Kastenmeier, Harold M. Erickson, Jonathan G. Brumbach, Matthew G. Whitten, Aida Albanil, Dean Y. Li, Sung Wan Kim, David A. Bull. (2008) Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction. Journal of Controlled Release 132:3, 260-266
CrossRef274
Masanori Miyazaki, Yasuhiro Ikeda, Yoshikazu Yonemitsu, Yoshinobu Goto, Ri-ichiro Kohno, Yusuke Murakami, Makoto Inoue, Yasuji Ueda, Mamoru Hasegawa, Shozo Tobimatsu, Katsuo Sueishi, Tatsuro Ishibashi. (2008) Synergistic neuroprotective effect via simian lentiviral vector-mediated simultaneous gene transfer of human pigment epithelium-derived factor and human fibroblast growth factor-2 in rodent models of retinitis pigmentosa. The Journal of Gene Medicine 10:12, 1273-1281
CrossRef275
Pedro R Lowenstein. (2008) A Call for Physiopathological Ethics. Molecular Therapy 16:11, 1771-1772
CrossRef276
Douglas M McCarty. (2008) Self-complementary AAV Vectors; Advances and Applications. Molecular Therapy 16:10, 1648-1656
CrossRef277
William W. Hauswirth, Tomas S. Aleman, Shalesh Kaushal, Artur V. Cideciyan, Sharon B. Schwartz, Lili Wang, Thomas J. Conlon, Sanford L. Boye, Terence R. Flotte, Barry J. Byrne, Samuel G. Jacobson. (2008) Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial. Human Gene Therapy 19:10, 979-990
CrossRef278
A. V. Cideciyan, T. S. Aleman, S. L. Boye, S. B. Schwartz, S. Kaushal, A. J. Roman, J.-j. Pang, A. Sumaroka, E. A. M. Windsor, J. M. Wilson, T. R. Flotte, G. A. Fishman, E. Heon, E. M. Stone, B. J. Byrne, S. G. Jacobson, W. W. Hauswirth. (2008) Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proceedings of the National Academy of Sciences 105:39, 15112-15117
CrossRef279
J W Bainbridge, R R Ali. (2008) Success in sight: The eyes have it! Ocular gene therapy trials for LCA look promising. Gene Therapy 15:17, 1191-1192
CrossRef280
Sami Ellouze, Sébastien Augustin, Aicha Bouaita, Crystel Bonnet, Manuel Simonutti, Valérie Forster, Serge Picaud, Jose-Alain Sahel, Marisol Corral-Debrinski. (2008) Optimized Allotopic Expression of the Human Mitochondrial ND4 Prevents Blindness in a Rat Model of Mitochondrial Dysfunction. The American Journal of Human Genetics 83:3, 373-387
CrossRef281
James Bainbridge, Robin Ali. (2008) Gene therapy for inherited childhood blindness shows promise. Expert Review of Ophthalmology 3:4, 357-359
CrossRef282
Marco Attilio Zarbin. (2008) Retinal Pigment Epithelium–Retina Transplantation for Retinal Degenerative Disease. American Journal of Ophthalmology 146:2, 151-153
CrossRef283
Anneke I. den Hollander, Ronald Roepman, Robert K. Koenekoop, Frans P.M. Cremers. (2008) Leber congenital amaurosis: Genes, proteins and disease mechanisms. Progress in Retinal and Eye Research 27:4, 391-419
CrossRef284
Rajendra Kumar-Singh. (2008) Barriers for retinal gene therapy: Separating fact from fiction. Vision Research 48:16, 1671-1680
CrossRef285
Alain Fischer, Marina Cavazzana-Calvo. (2008) Gene therapy of inherited diseases. The Lancet 371:9629, 2044-2047
CrossRef286
Miller, Joan W., . (2008) Preliminary Results of Gene Therapy for Retinal Degeneration. New England Journal of Medicine 358:21, 2282-2284
Full Text287
Robert K. Koenekoop. (2008) Successful RPE65 Gene Replacement and Improved Visual Function in Humans. Ophthalmic Genetics 29:3, 89-91
CrossRef
